methotrexate has been researched along with Central Nervous System Neoplasm in 595 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (7.23) | 18.2507 |
| 2000's | 175 (29.41) | 29.6817 |
| 2010's | 251 (42.18) | 24.3611 |
| 2020's | 126 (21.18) | 2.80 |
| Authors | Studies |
|---|---|
| Batchelor, T; Song, KW | 1 |
| Advani, R; Alharthy, H; Ayers, A; Ayers, EC; Barlow, CM; Barrett-Campbell, O; Caimi, PF; Chavez, JC; Cohen, J; David, KA; Del Prete, C; Echalier, B; Fu, T; Grover, NS; Hill, BT; Huntington, SF; Kahl, BS; Kallam, A; Kamdar, M; Karmali, R; Khan, N; Landsburg, DJ; Lansigan, F; Law, J; Lazaryan, A; Lee, J; Liu, J; Liu, Y; Major, A; Malecek, MK; McCook, AA; Nakhoda, S; Ollila, TA; Olszewski, A; Orellana-Noia, VM; Portell, CA; Raghunathan, V; Reed, DR; Rojek, AE; Romancik, J; Saeed, H; Sen, JM; Shah, H; Smith, SM; Snow, A; Sohail, MA; Spinner, MA; Spurgeon, SE; Stephens, DM; Switchenko, J; Voorhees, TJ; Watkins, M; Yellala, A | 1 |
| Balikov, DA; Betz, BL; Cani, AK; Chinnaiyan, AM; Devisetty, LV; Hu, K; Liu, CJ; Rao, RC; Tomlins, SA; Venneti, S | 1 |
| Chiattone, C; Federico, M; Ferreri, AJM; Fischer, T; Zing, N | 1 |
| Fujiwara, S; Imoto, N; Ishihara, S; Ito, R; Kurahashi, S; Sakai, T; Sugiura, I; Suzuki, Y; Yamamoto, S | 1 |
| Grommes, C; Schaff, LR | 2 |
| Grommes, C; Modelevsky, L; Reiss, SN; Yerram, P | 1 |
| Azumi, M; Fujihara, T; Mizobuchi, Y; Nakajima, K; Takagi, Y | 1 |
| Chukwueke, U; Grommes, C; Nayak, L | 1 |
| Bansal, R; Bhojwani, D; Wayne, AS | 1 |
| Anzalone, N; Bernardi, M; Calimeri, T; Ferreri, AJ; Mastaglio, S; Steffanoni, S | 1 |
| Barraclough, A; Gregory, GP; Hamad, N; Keane, C; Ku, M; Lee, YY; Swain, F; Talaulikar, D; Tatarczuch, M; Wight, J | 1 |
| Deng, X; Luo, X; Wang, X; Zhang, Q; Zhang, Y; Zhu, Y | 1 |
| Fukuo, Y; Futamura, G; Hiramatsu, R; Hu, N; Kashiwagi, H; Kawabata, S; Miyatake, SI; Suzuki, M; Takata, T; Takeuchi, K; Tanaka, H; Wanibuchi, M; Watanabe, T; Yoshimura, K | 1 |
| Agbetiafa, K; Ahearne, M; Barlow, BR; Calimeri, T; Cheah, CY; Choquet, S; Clavert, A; Cwynarski, K; Durot, E; Ebsworth, TJ; El Galaly, TC; Elliot, J; Eyre, TA; Fernandez, R; Ferreri, AJM; Forgeard, N; Fox, CP; Gounder, P; Guidetti, A; Hamad, N; Htut, TW; Khwaja, J; Kirkwood, AA; Ku, M; Lebras, L; Lees, C; Lewis, KL; Liu, Q; Lombion, N; Lopez-Garcia, A; Manos, K; Martinez-Calle, N; McIlroy, G; McKay, P; Miall, F; Moles-Moreau, MP; Narkhede, M; O'Mahony, D; Preston, G; Renaud, L; Ricard, L; Roulin, L; Rusconi, C; Santarsieri, A; Schorb, E; Scott, H; Shah, N; Smith, J; Soussain, C; Strüßmann, T; Tchernonog, E; Vassallo, F; Wilson, MR; Wong Doo, N; Zayac, AS; Øvlisen, AK | 1 |
| Shu, HS; Wang, DW; Zhang, Q | 1 |
| McNeer, JL; Schmiegelow, K | 1 |
| Acosta, EP; Carlow, D; DeAngelis, LM; Gavrilovic, IT; Grommes, C; Lobbous, M; Mellinghoff, IK; Miller, AM; Nabors, LB; Piotrowski, AF; Ryan, KJ; Schaff, LR; Schofield, R; Sener, U; Skakodub, A; Stone, JB | 1 |
| Akagi, Y; Hosoi, H; Iwamoto, R; Kosako, H; Matsufusa, T; Murata, S; Murata, SI; Mushino, T; Okamura, T; Sonoki, T | 1 |
| Flórez, A; Patiño, J; Rivera, JS; Toro, J | 1 |
| Cho, D; Cho, J; Jo, H; Kang, ES; Kim, SJ; Kim, WS; Yoon, SE | 1 |
| Fortin Ensign, SP; Gathers, D; Mrugala, MM; Wiedmeier, JE | 1 |
| Hilal, T; Jain, SP | 1 |
| Abdelrashid, M; DeAtkine, AB; Fiveash, JB; Kim, J; Lobbous, M; Markert, JM; Mehta, A; Nabors, LB; Oster, RA; Tucker, Z | 1 |
| Chua, N; Puckrin, R; Shafey, M; Stewart, DA | 1 |
| Fiori, S; Ismail, A; Radice, T; Ramadan, S; Tarella, C | 1 |
| Avni, B; Gatt, ME; Goldschmidt, N; Grisaro, S; Gural, A; Lavie, D; Lebel, E; Linetski, E; Lossos, A; Makranz, C; Nachmias, B; Rosenberg, S; Saban, R; Shaulov, A; Siegal, T; Vainstein, V; Zimran, E | 1 |
| Balzarotti, M; Binder, M; Burger, E; Cabras, G; Cavalli, F; Celico, C; Cozens, K; Cwynarski, K; Deckert, M; Fabbri, A; Falautano, M; Ferranti, A; Ferreri, AJM; Finke, J; Fox, CP; Gørløv, JS; Hemmaway, C; Hertenstein, B; Hess, G; Ielmini, N; Ilariucci, F; Illerhaus, G; Johnson, PW; Keller, U; Krampera, M; Krause, SW; La Rosée, P; Linton, KM; Nonis, A; Orsucci, L; Panse, J; Pennese, E; Pisani, F; Politi, LS; Ponzoni, M; Pukrop, T; Pulczynski, E; Roth, A; Rummel, M; Schmoll, HJ; Schorb, E; Smith, J; Stilgenbauer, S; Thurner, L; Tucci, A; Zanni, M; Zucca, E | 1 |
| Ahle, G; Charlotte, F; Choquet, S; Dehais, C; Desjardins, C; Hoang-Xuan, K; Houillier, C; Larrieu-Ciron, D; Le Garff-Tavernier, M; Mathon, B; Mokhtari, K; Morales-Martinez, A; Nichelli, L | 1 |
| Cohen, AL; Colman, H; Gelhard, S; Maxwell, A; Mendez, JS | 1 |
| Chen, X; Li, Z; Lin, Z; Liu, L; Xu, B; Zeng, H | 1 |
| Kowalski, T; Nilius-Eliliwi, V; Schlegel, U; Schroers, R; Seidel, S | 1 |
| Fujita, M; Nakao, T; Okuda, T; Takahashi, JC; Yoshioka, H | 1 |
| Faria, MJ; Fernanda, T; Rita, D; Rui, B | 1 |
| Bobillo, S; Cheah, CY; Cwynarski, K; El-Galaly, TC; Evens, AM; Eyre, TA; Ferreri, AJM; Lewis, KL; Maurer, MJ; McKay, P; Savage, KJ; Villa, D; Wilson, MR | 1 |
| Cwynarski, K; Fox, CP; Fricker, H; Ihorst, G; Illerhaus, G; Isbell, LK; Neumaier, S; Okosun, J; Scherer, F; Schorb, E; Steinheber, C; Valk, E; Wendler, J | 1 |
| Abousaud, A; Orellana-Noia, V | 1 |
| Cao, A; Chen, H; Chen, L; Du, P; Geng, D; Liu, X; Shen, L; Wu, X | 1 |
| Chang, Q; Chen, H; Chen, T; Chen, Y; Geng, D; Jiang, T; Lei, J; Li, J; Li, W; Li, XQ; Li, Y; Lin, S; Liu, Y; Lu, D; Lyu, L; Mao, Y; Qiu, X; Song, Y; Wang, B; Wang, Y; Wang, Z; Wu, J; Yu, JT; Zhang, X; Zhuang, D | 1 |
| Nagane, M | 1 |
| Baehring, JM; Kaulen, LD | 1 |
| Liu, B; Shi, X; Wang, Z; Xie, X; Xu, D; Zhang, N | 1 |
| Araújo Soares, V; Culler, HF; de Oliveira Costa, R; de Pádua Covas Lage, LA; Jacomassi, MD; Meneguin, TD; Pereira, J; Reichert, CO; Reis, DGC; Rocha, V; Zerbini, MCN | 1 |
| Cheah, CY; Lewis, KL | 1 |
| Al-Athamen, K; Barrett, O; Gourevitch, A; Gozlan, A; Grinbaum, U; Kaisman-Elbaz, T; Levi, E; Peles, I; Porges, T; Rabinovich, A; Zektser, M | 1 |
| Abe, K; Arakawa, Y; Asai, A; Asano, K; Fukuda, H; Gomyo, M; Katayama, H; Kinoshita, M; Koga, T; Kojima, M; Mishima, K; Mizusawa, J; Momii, Y; Nagane, M; Nakamura, S; Narita, Y; Natsumeda, M; Nishikawa, R; Sasaki, A; Sasaki, H; Sasaki, N; Sasayama, T; Shibahara, I; Shinojima, N; Sumi, M; Tamaru, JI; Tsuchiya, K; Tsurubuchi, T; Yamasaki, F; Yoshimoto, K | 1 |
| MacDonald, D; Nair, VJ; Samant, R; Song, J; Volpini, ME | 1 |
| Curry, LD; Iragavarapu, C; Keller, P; Krem, MM; Li, N; Monohan, GP; Munker, R; Nozad, S; Pryor, P; Yan, D | 1 |
| Bobillo, S; Cwynarski, K; Ferreri, AJM; Khwaja, J | 1 |
| Berinstein, N; Crump, M; Drori, AK; Hicks, LK; Kridel, R; Liu, J; Prica, A; Suleman, A | 1 |
| Aoki, K; Hirano, M; Ito, S; Kano, T; Kitano, Y; Kondo, Y; Kurahashi, S; Lushun, C; Maeda, S; Mizutani, N; Motomura, K; Nagata, Y; Natsume, A; Ohka, F; Ohno, M; Oyama, H; Saito, R; Seki, Y; Shimizu, H; Suzaki, N; Takasu, S; Takeuchi, K; Tanahashi, K; Wakabayashi, K; Wakabayashi, T; Yamaguchi, J; Yamazaki, S | 1 |
| Bobillo, S; Cwynarski, K; Wilson, MR | 2 |
| Dabaja, BS; Fang, PQ; Nasr, L; Short, NJ; Wu, SY | 1 |
| Huang, Y; Jiang, H; Liang, Y; Qian, W; Xu, X; Yu, T; Yuan, X | 1 |
| Cheng, CL; Fang, WQ; Hou, HA; Lin, CP; Ma, WL; Tien, HF; Tsai, CH; Yeh, PT | 1 |
| Cho, SG; Choi, BO; Jeon, YW; Kim, TY; Min, GJ; O, JH; Park, G; Park, YH | 1 |
| Borawska, A; Dabrowska-Iwanicka, A; Domanska-Czyz, K; Druzd-Sitek, A; Konecki, R; Kotarska, M; Lapinska, G; Michalski, W; Mroz-Zycinska, E; Osiadacz, W; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Poplawska, L; Romejko-Jarosinska, J; Rymkiewicz, G; Swierkowska, M; Szymanski, M; Tajer, J; Targonski, L; Walewski, J; Wojciechowska-Lampka, E; Wojewodzka-Mirocha, M | 1 |
| Agrawal, P; Bachanova, V; Berg, S; Bond, DA; Cai, J; Carter, J; Chang, J; Cleveland, J; David, KA; Epperla, N; Evens, AM; Folstad, M; Glantz, M; Goldlust, SA; Graber, J; Habib, A; Hossain, N; Kahl, B; Karmali, R; Kim, MS; Kim, SH; Kumar, P; Lin, Y; Major, A; Malecek, MK; Martin, P; Mier-Hicks, A; Naik, S; Ney, D; Ollila, TA; Rajakumar, P; Reddy, N; Rubenstein, J; Salman, S; Sieg, A; Singer, S; Smith, SM; Spurgeon, S; Strouse, C; Sundaram, S; Torka, P; Tsang, M; Vaca, R; Vendiola, JA; Venugopal, P; Zayac, A | 1 |
| Andayani, YD; Andriani, M; Diansari, Y; Djamaludin, N; Syahrir, M; Wirdah, A | 1 |
| Chan, A; Ciurea, SO; Doh, J; Griffin, SP; Jeyakumar, D; Kongtim, P; Lee, BJ; O'Brien, S | 1 |
| Akita, T; Asano, K; Fudaba, H; Fujii, K; Hosoya, T; Ideguchi, M; Kakuta, K; Kambe, A; Katayama, K; Kawasaki, Y; Koizumi, S; Kurozumi, K; Nagashima, H; Nakayama, N; Natsumeda, M; Nishibuchi, I; Nishizaki, T; Sasayama, T; Shimabukuro, T; Sugiyama, K; Taguchi, K; Tanaka, K; Tsukamoto, Y; Yamasaki, F; Yasutomo, M; Yonezawa, U; Yoshida, K | 1 |
| Bennett, R; Berkahn, L; Christophers, M; Coomarasamy, C; Issa, S; Jackson, S; Ruskova, A; Theakston, E; Wong, S | 1 |
| Liu, R; Qin, Y; Ren, C; Wu, D; Zhang, W; Zhang, X | 1 |
| Chen, H; Duan, X; Lin, D; Liu, H; Miao, C; Nie, T; Wu, J; Zhang, X; Zheng, Y; Zhong, W | 1 |
| Cwynarski, K; Khwaja, J | 1 |
| Ahrweiller, F; Alfonsi, M; Ammarguellat, H; Antoni, D; Belkacemi, Y; Benchalal, M; Bernier-Chastagner, V; Colin, P; Coutte, A; Créhange, G; Dadoun, N; Feuvret, L; Hamidou, H; Hoang-Xuan, K; Houillier, C; Jacob, J; Jouglar, E; Lang, P; Pointreau, Y; Soussain, C; Thomas-Joulié, A; Vieillot, S | 1 |
| DeAngelis, LM; Grommes, C; Nandakumar, S; Omuro, AMP; Schaff, LR; Therkelsen, KE | 1 |
| Baba, S; Hiu, T; Imaizumi, Y; Izumo, T; Kato, T; Matsuo, A; Matsuo, T; Miyazaki, Y; Morimoto, S; Morofuji, Y; Niino, D; Okano, S; Ujifuku, K; Yamaguchi, S; Yoshida, K; Yoshida, M | 1 |
| Miyazaki, K | 1 |
| Mishra, P; Moharana, B; Palanisamy, S; Parija, S | 1 |
| Akhtari, M; Brothers, J; Cao, H; Hino, C; Lacy, C; Mirshahidi, H; Park, K | 1 |
| Bao, H; Cao, B; Cen, X; Gao, Y; Liang, R; Liu, A; Qin, Y; Shi, Y; Wang, J; Wang, N; Xie, Y; Xue, M; Yang, Y; Zhang, H; Zhang, L; Zhang, M; Zhang, Q; Zhang, W; Zhao, Y; Zhong, K | 1 |
| Bishton, MJ; Cheah, CY; Cwynarski, K; El-Galaly, TC; Eyre, TA; Fox, CP; Hawkes, EA; Jakobsen, LH; Lewis, KL; Maurer, MJ; Savage, KJ; Smedby, KE; Villa, D | 1 |
| Amatya, VJ; Horie, N; Khairunnisa, NI; Onishi, S; Ozono, I; Taguchi, A; Takayasu, T; Takeshima, Y; Yamasaki, F; Yonezawa, U | 1 |
| Gao, J; Peng, X; Wang, L | 1 |
| Hayano, A; Hondoh, H; Ikenaka, K; Kano, Y; Takashima, Y; Yamanaka, R; Yoshimura, T | 1 |
| Ambinder, R; Dzaye, O; Estephan, F; Gladstone, DE; Grossman, SA; Holdhoff, M; Kamson, DO; Lambrecht, S; Lin, DDM; Swinnen, L; Wagner-Johnston, N; Ye, X | 1 |
| Bazan, F; Chaigneau, L; Curtit, E; Dobi, E; Mansi, L; Menneveau, N; Meynard, G; Paillard, MJ; Pivot, X; Royer, B; Villanueva, C | 1 |
| Chen, C; Ma, X; Wei, X; Zhuo, H | 1 |
| Bai, T; Dai, X; Guo, Z; Li, Y; Lu, Q; Tian, X; Yao, J; Zhang, Y; Zhong, Y | 1 |
| Chong, G; Churilov, L; Garwood, MJ; Hawkes, EA | 1 |
| Chen, H; Liu, Z; Xu, J; Yang, J; Yang, Y | 1 |
| Pan, E; Singh, PK | 1 |
| Abraham, J; Agapé, P; Ahle, G; Aidaoui, B; Alentorn, A; Amiel, A; Bay, JO; Blonski, M; Boyle, E; Campello, C; Casasnovas, O; Cassoux, N; Charlotte, F; Chauchet, A; Chebrek, S; Chinot, O; Choquet, S; Colin, P; Costopoulos, M; Damaj, G; Delgadillo, D; Delwail, V; Douzane, H; Fabbro, M; Feuvret, L; Fornecker, LM; Genet, D; Ghesquières, H; Gressin, R; Gyan, E; Haioun, C; Hoang-Xuan, K; Houillier, C; Houot, R; Jardin, F; Kas, A; Lamy, T; Laribi, K; Le Garff-Tavernier, M; Marolleau, JP; Martin-Duverneuil, N; Mathon, B; Mokhtari, K; Moles-Moreau, MP; Moluçon-Chabrot, C; Morschhauser, F; Oberic, L; Peyre, M; Schmitt, A; Serrier, C; Soubeyran, P; Soussain, C; Tabouret, E; Taillandier, L; Tamburini, J; Tempescul, A; Touitou, V; Waultier, A | 1 |
| Beca, JM; Keech, J; Kouroukis, CT; Mow, E; Raza, K | 1 |
| Calimeri, T; Cummin, T; Cwynarski, K; De Marco, B; Eyre, TA; Fabbri, A; Ferreri, AJM; Fox, CP; Illerhaus, G; Kasenda, B; Krampera, M; Linton, K; Martinez-Calle, N; Ninkovic, S; Orsucci, L; Schorb, E; Smith, J; Trefz, S; Yallop, D | 1 |
| Aldrees, S; Jeeva-Patel, T; Margolin, E | 1 |
| Debacker, KC; Derstine, B; Pai, MP; Su, GL; Sullivan, J; Wang, SC | 1 |
| Beham-Schmid, C; Deutsch, A; Greinix, H; Hatzl, S; Neumeister, P; Pichler, M; Posch, F; Prochazka, KT; Stöger, H | 1 |
| Hayano, A; Takashima, Y; Yamanaka, R | 2 |
| Abboud, MR; Chahrour, M; El-Khoury, H; El-Solh, H; Ghanem, KM; Hamideh, D; Muwakkit, SA; Saab, R; Saifi, O; Tamim, H; Tarek, N | 1 |
| Alchawaf, A; Buckley, H; Culligan, DJ; Cwynarski, K; Eyre, TA; Fourali, S; Fox, CP; Horan, M; Kassam, S; Kelsey, P; Lim, YJ; Linton, K; Martinez-Calle, N; McCulloch, R; McKay, P; Ngu, L; Osborne, W; Poynton, E; Rafferty, M; Rowntree, C; Scott, G; Smith, J; Wright, J; Yallop, D | 1 |
| Kaneko, K; Kawazoe, M; Nanki, T | 1 |
| Liu, F; Xun, Y; Yang, A; Yang, H; You, H | 1 |
| Fukai, J; Hamano, M; Hondoh, H; Iwadate, Y; Kajiwara, K; Kobayashi, T; Takashima, Y; Yamanaka, R | 1 |
| Zhang, Y; Zhou, DB | 1 |
| Kobayashi, K; Lee, J; Nagane, M; Saito, K; Sasaki, N; Shibahara, J; Shimizu, S; Shiokawa, Y; Suzuki, K; Takayama, N; Yamagishi, Y | 1 |
| Alañá, M; Barbero-Bordallo, N; Barceló, MI; Barón, M; Bobillo, S; Bruna, J; Caballero, AC; Cacabelos, P; Caldú Agud, R; Camro, I; Dlouhy, I; Encuentra, M; Erro, ME; Estela, J; Gállego Pérez-Larraya, J; García Molina, E; García-Catalán, G; Gómez-Vicente, L; Graus, F; Huertas, N; Ibáñez-Juliá, MJ; Lado, T; Martínez, P; Mercadal, S; Muntañola, A; Salar, A; Sancho, JM; Solé-Rodríguez, M; Velasco, R; Vidal, N | 1 |
| Haapasaari, KM; Jantunen, E; Kaprio, E; Karihtala, P; Kauppila, S; Kuittinen, O; Kuitunen, H; Kuusisto, M; Makkonen, V; Turpeenniemi-Hujanen, T | 1 |
| Byeon, S; Cho, J; Hur, JY; Jeong, H; Kim, EJ; Kim, H; Kim, SJ; Kim, WS; Ko, YH; Koh, Y; Miyazaki, K; Oguchi, M; Sohn, I; Suzuki, R; Taguchi, S; Yamaguchi, M; Yoon, DH; Yoon, SE; Yoon, SS | 1 |
| George, J; Goncalves, PH; Jaffe, ES; Little, RF; Lurain, K; Martin, S; Pittaluga, S; Polizzotto, MN; Ramaswami, R; Steinberg, SM; Tamula, MA; Uldrick, TS; Wang, HW; Widell, A; Wolters, PL; Yarchoan, R; Yuan, CM | 1 |
| Juul-Jensen, K; Larsen, TS; Møller, MB; Pedersen, CB; Poulsen, FR; Schulz, MK; Sommer-Sørensen, R | 1 |
| Ahearne, M; Cheung, CK; Creasey, T; Cwynarski, K; Elliot, J; Eyre, TA; Fox, CP; Khwaja, J; Linton, K; Martinez-Calle, N; McKay, P; Miall, F; Mula Kh, A; Parsons, KE; Preston, G; Schofield, J; Shah, N; Smith, J; Timmins, MA; Wilson, MR | 1 |
| Bazargan, A; Filshie, R; Gilberston, M; Gregory, GP; Ku, M; Opat, S; Paul, E; Quach, H; Shortt, J; Tam, C; Tatarczuch, M; Tey, A | 1 |
| Bode, U; Deckert, M; Egerer, G; Engert, A; Fimmers, R; Fliessbach, K; Herrlinger, U; Klockgether, T; Kowoll, A; Kroschinsky, F; Pels, H; Reichmann, H; Schackert, G; Schlegel, U; Schlömer, S; Schmidt-Wolf, IGH; Seidel, S; Vogt-Schaden, M | 1 |
| Chen, F; Guo, H; Huang, L; Jiang, X; Li, W; Liang, Z; Liu, S; Ou, Q; Pang, D; Wei, X; Wu, X; Zhou, D | 1 |
| Chang, X; Guo, Y; Hu, R; Hui, W; Su, L; Sun, W; Zhang, Y; Zhao, H | 1 |
| Avivi, I; Blumenthal, DT; Bokstein, F; Gibstein, L; Perry, C; Ram, R; Sarid, N; Weiss-Meilik, A | 1 |
| Grommes, C; Holdhoff, M; Kaley, TJ; Mrugala, MM; Nayak, L; Perez-Heydrich, C; Swinnen, LJ | 1 |
| Ballester, LY; Choi, HA; Dono, A; Esquenazi, Y; Hasbun, R; Husein, N; Ybarra, C | 1 |
| Bairey, O; Shargian-Alon, L; Siegal, T | 1 |
| Grommes, C | 1 |
| Alonso, JR; Alvarez-Pinzon, AM; Borro, M; Herrera, D; Valerio, JE; Wolf, A | 1 |
| Enya, M; Hirota, T; Horikawa, Y; Iizuka, K; Iwama, T; Kato, T; Kito, Y; Kuwabara-Ohmura, Y; Liu, Y; Miyazaki, T; Mizuno, M; Nonomura, K; Ohe, N; Saigo, C; Suwa, T; Takao, K; Tani, A; Yabe, D | 1 |
| Asou, D; Fudaba, H; Fujiki, M; Hirakawa, T; Kawasaki, Y; Matsushita, W; Momii, Y; Onishi, K; Sugita, K | 1 |
| Du, H; Xiao, H; Ye, X; Yu, J; Zhang, L | 1 |
| Bakunina, K; Bromberg, JEC; Dirven, L; Doorduijn, JK; Issa, S; van den Bent, MJ; van der Meulen, M | 1 |
| El Darsa, H; Ghosh, S; Owen, C; Peters, A; Puckrin, R; Stewart, D | 1 |
| Chae, EJ; Chae, H; Cho, H; Huh, J; Jeong, H; Kim, H; Kim, KW; Kim, S; Lee, JB; Lee, K; Lee, SW; Park, CS; Ryu, JS; Suh, C; Yoon, DH | 1 |
| Balke-Want, H; Borchmann, P; Bröckelmann, PJ; Deckert, M; Gillessen, S; Gödel, P; Heger, JM; Kreissl, S; Naendrup, JH; Sieg, N; Simon, F; von Tresckow, B | 1 |
| Ikeda, R; Ohno, R; Saito, K; Takeshima, H; Tazaki, T; Urata, S; Yoshikawa, N | 1 |
| Puckrin, R; Stewart, DA | 1 |
| Cwynarski, K; Eyre, TA; Fox, CP; Martinez-Calle, N; McKay, P; Wilson, MR | 1 |
| Duell, J; Einsele, H; Gerhard-Hartmann, E; Heidemeier, A; Krummenast, FC; Rosenwald, A; Steinhardt, MJ; Topp, MS | 1 |
| Batlevi, CL; Bobillo, S; Caron, PC; Dogan, A; Ghione, P; Hamilton, A; Hamlin, PA; Horwitz, SM; Joffe, E; Kumar, A; Matasar, MJ; Mondello, P; Moskowitz, A; Noy, A; Owens, CN; Palomba, ML; Sermer, D; Seshan, VE; Straus, D; von Keudell, G; Younes, A; Zelenetz, AD | 1 |
| Dharnidharka, VR; Hayashi, RJ; Semkiu, KM | 1 |
| Kiyoi, H; Shimada, K | 1 |
| Kim, N; Kim, SJ; Kim, WS; Lim, DH; Yoon, SE | 1 |
| Adlington, J; Auer, D; Bessell, EM; Bishton, MJ; Byrne, P; Figueroa, R; Fox, CP; Grainge, MJ; James, E; Kaji, FA; Martinez-Calle, N; O'Donoghue, M; Paine, S; Smith, S; Sovani, V | 1 |
| Chen, Y; Chng, WJ; de Mel, S; Goh, YT; Grigoropoulos, NF; Lee, YS; Lim, ST; Liu, X; Nagarajan, C; Ng, LCK; Ong, SY; Phipps, C; Tan, MSY; Tan, YC; Yong, KY | 1 |
| Armand, P; Batchelor, TT; Chen, YB; DeFilipp, Z; El-Jawahri, A; Li, S; Nayak, L; Wang, N | 1 |
| Bai, X; Chen, Y; Ji, N; Liu, F; Liu, J; Liu, Y; Qian, J; Qiu, X; Sun, S; Sun, X; Wang, Y; Zhu, H | 1 |
| Chang, JH; Cheong, JW; Cho, H; Jang, JE; Kim, JS; Kim, SH; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Suh, CO; Yang, WI | 1 |
| Borowitz, MJ; Carroll, A; Carroll, WL; Chen, S; Devidas, M; Gastier-Foster, JM; Heerema, NA; Hunger, SP; Larsen, E; Loh, ML; Maloney, K; Mattano, L; Raetz, E; Willman, C; Winick, N; Wood, B | 1 |
| Huh, J; Jo, JC; Kang, EH; Kim, JH; Kim, S; Lee, K; Lee, SW; Park, CS; Park, JS; Ryu, JS; Suh, C; Yoon, DH | 1 |
| Eckert, C; Izraeli, S | 1 |
| Chiba, S; Hasegawa, Y; Hattori, K; Ishikawa, E; Kato, T; Kurita, N; Matsumura, A; Obara, N; Okoshi, Y; Sakata-Yanagimoto, M; Takano, S; Yamamoto, T; Yokoyama, Y | 1 |
| Glass, J | 1 |
| Chalise, L; Hara, M; Hirano, M; Motomura, K; Natsume, A; Nishimura, Y; Ohka, F; Wakabayashi, T | 1 |
| Ahn, YC; Kim, K; Kim, SJ; Kim, WS; Lim, DH; Park, JS; Park, W | 1 |
| Katai, H; Miyakita, Y; Muragaki, Y; Narita, Y; Ohno, M; Takahashi, M | 1 |
| Kamma, H; Kobayashi, K; Lee, J; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K | 1 |
| Jin, J; Mao, L; Wang, H; Wang, L; Wang, M; Wei, J | 1 |
| Gu, CH; Gu, WW; Mou, K; Qi, JD | 1 |
| Batchelor, TT; Han, CH | 1 |
| Di Palma, G; Gioulis, M; Marsala, SZ; Pistacchi, M; Sanson, F | 1 |
| Han, X; Ji, Y; Ouyang, M; Zhou, D; Zhu, T | 1 |
| Ferreri, AJM | 1 |
| Savage, KJ | 1 |
| Goto, T; Nagura, E; Nakashima, M; Okamoto, S; Tanaka, M | 1 |
| Chihara, D; Oki, Y | 1 |
| Fujimoto, K; Jono, H; Kuratsu, JI; Makino, K; Mikami, Y; Mukasa, A; Nakamura, H; Nakamura, K; Oda, K; Shinojima, N; Todaka, K; Yamada, K; Yano, S | 1 |
| Gondi, V; Lukas, RV; Raizer, JJ; Stupp, R | 1 |
| El Rassy, E; Ghosn, M; Hanna, C; Irani, C; Villa, D | 1 |
| Fröhling, S; Glimm, H; Hurtz, HJ; Hutter, B; Jordan, K; Klink, B; Müller, LP; Rüssel, J; Stenzinger, A; Stögbauer, F; Terziev, D; Weber, T; Wickenhauser, C | 1 |
| Adhikari, N; Bhasker, S; Biswas, A; Chander, S; Chawla, R; Garg, A; Gogia, A; Joshi, G; Kumar, L; Nehra, A; Sahoo, RK; Sharma, MC; Singh, M; Sreenivas, V | 1 |
| Dasanu, CA; Del Rosario, M; Tsai, H | 1 |
| Kacem, K; Zriba, S | 1 |
| Hoang-Xuan, K | 1 |
| Cui, Y; Du, Y; Lin, S; Mei, S; Ren, X; Shi, X; Yu, K; Zeng, C; Zhao, Z | 1 |
| Cohen, JB; Flowers, CR; Hall, KH; Panjic, EH; Valla, K | 1 |
| Azadi, A; Heidari, R; Mohammadi-Samani, S; Pourtalebi Jahromi, L | 1 |
| Clavert, A; Farhi, J; Hamel, JF; Hunault-Berger, M; Laribi, K; Mercier, M; Moles-Moreau, MP; Orvain, C; Rousselet, MC; Sutra Del Galy, A; Tanguy-Schmidt, A | 1 |
| Chang, Y; Duan, L; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Tian, L; Wang, X; Wu, J; Yan, J; Yu, H; Zhang, L; Zhang, M; Zhang, X | 1 |
| Kansara, R | 1 |
| DeAngelis, LM; Graham, MS | 1 |
| Korfel, A; Schlegel, U | 1 |
| Chen, B; Chen, K; Ding, T; Fan, N; Kang, H; Lai, J; Lin, Z; Ma, J; Ma, Y; Wang, Q; Xu, X; Yuan, Y; Zeng, Q; Zhuang, L | 1 |
| Brown, C; Chadban, S; Saunders, J; Thiagarajah, N; Vaughan, E; Yeung, J | 1 |
| Le, Y; Li, H; Liu, Z; Long, Y; Wan, C | 1 |
| Batchelor, TT; DeAngelis, LM; Ferreri, AJM; Grommes, C; Rubenstein, JL | 1 |
| Gowarty, JL; Herrington, JD; Patel, IJ | 1 |
| Hoang-Xuan, K; Houillier, C; Royer-Perron, L | 1 |
| Berger, MF; Campos, C; Codega, P; Daras, M; DeAngelis, LM; Grommes, C; Hatzoglou, V; Kaley, TJ; Lin, A; Manne, M; Mellinghoff, IK; Nolan, CP; Panageas, KS; Pentsova, EI; Piotrowski, AF; Reiner, AS; Stone, J; Tang, SS; Thomas, AA; Viale, A; Wolfe, J | 1 |
| Baars, JW; Bakunina, K; Beeker, A; Beijert, M; Bromberg, JEC; Cull, G; de Jong, D; Doorduijn, JK; Durian, M; Gonzales, M; Issa, S; Mason, KD; Minnema, MC; Nijland, M; Schouten, HC; Seute, T; Stevens, WBC; van den Bent, MJ; Zijlstra, JM | 1 |
| Adhikari, N; Bakhshi, S; Biswas, A; Gopinathan, VR; Sharma, MC | 1 |
| Dann, EJ; Darawshy, F; Gatt, ME; Goldschmidt, N; Heffes, V; Horowitz, NA; Mashiach, T; Shaulov, A | 1 |
| Endou, S; Houkin, K; Kaneko, S; Kobayashi, H; Motegi, H; Onimaru, R; Terasaka, S; Yamaguchi, S | 1 |
| Adhikari, N; Baghmar, S; Bakhshi, S; Batra, A; Biswas, A; Garg, A; Gogia, A; Kumar, L; Mohanti, BK; Patekar, M; Raina, V; Sahoo, RK; Sharma, A; Sharma, MC; Thulkar, S; Vishnubhatla, S | 1 |
| Bi, X; Chen, C; Chen, H; Cui, J; Jiang, W; Li, ZM; Liu, P; Nie, M; Sun, P; Wang, Y; Xia, Y; Yan, S; Yang, H; Zhang, XW | 1 |
| Alpdogan, O; Gong, J; Palmisiano, N; Rhoades, R | 1 |
| Abdalla, K; AlAzmi, AA; Algamal, A; Elimam, N; Felimban, S; Jastaniah, W | 1 |
| Aaroe, AE; Nevel, KS | 1 |
| Kamada, H; Takahashi, Y; Tempaku, A | 1 |
| Hong, JY; Huh, J; Kang, EH; Kim, S; Lee, K; Lee, SW; Park, CS; Suh, C; Yoon, DH | 1 |
| Allan, JN; Van Besien, K | 1 |
| Irie, J; Matsuo, M; Mutsukura, K; Tateishi, Y; Tokuda, M; Yamashita, A | 1 |
| Avigdor, A; Avivi, I; Bairey, O; Ben Barouch, S; Goldschmidt, N; Herishanu, Y; Horowitz, N; Lavi, N; Lebel, E; Perry, C; Ram, R; Sarid, N; Shvidel, L; Sofer, O | 1 |
| Bishton, M; Booth, S; Collins, GP; Eyre, TA; Fields, P; Fox, CP; Griffith, J; Gunawan, A; Hatton, CSR; Hildyard, C; Kirkwood, AA; Martinez-Calle, N; McMillan, A; Mercer, C; Oliver, R; Plaschkes, H; Wolf, J | 1 |
| Cheah, CY; Chin, C; Coombes, C; Dickinson, M; Gasiorowski, R; Gregory, GP; Hawkes, EA; Johnston, A; Keane, C; Ku, M; Lam, S; Linton, K; Minson, A; Talaulikar, D; Wai, SH; Wight, JC; Yue, M | 1 |
| Bertoni, F; Mian, M; Mondello, P | 1 |
| Castellino, A; Chiappella, A; Nicolosi, M; Novo, M; Santambrogio, E; Vassallo, F; Vitolo, U | 1 |
| Brenner, A; Butler, MJ; Faivre, G; Le, I | 1 |
| Belada, D; Malý, J; Motyčková, M; Smolej, L; Zák, P | 1 |
| Doucet, S; Kumthekar, P; Raizer, J | 1 |
| Avilés, A; Jesús Nambo, M; Neri, N | 1 |
| Abikhair, M; Arumugaswamy, A; Bajel, A; Chan, KL; Cher, L; Gregory, G; Grigg, A; Leung, T; Opat, S; Ritchie, D; Tam, C | 1 |
| Fang, BM; Jiang, JH; Xu, YH | 1 |
| Belotti, A; Cecchetti, C; Elli, EM; Fedele, M; Parma, M; Pogliani, EM; Realini, S | 1 |
| Butler, RW; Calabrese, P; Doolittle, ND; Dósa, E; Fu, R; Hedrick, N; Illerhaus, G; Jahnke, K; Korfel, A; Kraemer, DF; Lubow, MA; Maron, LM; Muldoon, LL; Neuwelt, EA; Rogowski, S; Schlegel, U; Schorb, E; Tyson, RM | 1 |
| Bell, SL; James, A; Muirhead, R; Murray, EC; Stewart, W | 1 |
| Fukushima, M; Katayama, Y; Kotani, A; Kura, Y; Sawada, U; Yokose, N; Yoshino, A | 1 |
| Brugières, L; Le Deley, MC; Marky, I; Mori, T; Reiter, A; Rosolen, A; Uyttebroeck, A; Williams, D; Woessman, W; Wrobel, G; Zsiros, J | 1 |
| Choi, MK; Hoon Lim, D; Kang, ES; Kim, DW; Kim, SJ; Kim, WS; Ko, YH; Park, JH; Pyo, DH; Seok, H | 1 |
| Abromowitch, M; Finlay, JL; Gross, TG; Lones, M; Perkins, SL; Smith, LM; Termuhlen, AM; Weinstein, H | 1 |
| Batchelor, TT; Nayak, L | 1 |
| Bachour, M; Hussein, T; Kenj, M; Salamoon, M | 1 |
| Kennedy, GA; Morris, K; O'Rourke, K | 1 |
| Abrey, LE; Correa, DD; Curry, R; DeAngelis, LM; Grant, B; Grimm, S; Karimi, S; Lai, RK; Morris, PG; Omuro, A; Panageas, K; Raizer, JJ; Reiner, AS; Schiff, D; Shah, G; Yahalom, J | 1 |
| Benevolo, G; Chiappella, A; Vitolo, U | 1 |
| Batchelor, TT; Issa, S; Ponzoni, M; Rubenstein, JL | 1 |
| Abe, E; Harada, H; Ishibashi, N; Koizumi, M; Kubota, S; Matsushita, H; Miyawaki, D; Nomiya, T; Ogo, E; Ohmori, Y; Onishi, H; Onodera, S; Shibamoto, Y; Sugie, C; Sumi, M; Suzuki, K; Takahashi, I; Takemoto, M; Tamaki, Y; Tokumaru, S | 1 |
| Boyce, TG; Burnette, BL; Jentoft, MA; Porrata, LF; Witzig, TE | 1 |
| Atta, J; Brandts, C; Brodt, HR; Kann, G; Kiderlen, T; Stephan, C; Wolf, T | 1 |
| Deangelis, LM; Omuro, A; Pentsova, E | 1 |
| Ikegami, S; Iwadate, Y; Matsutani, T; Saeki, N; Shinozaki, N; Suganami, A; Tamura, Y; Yamanaka, R | 1 |
| Abrey, L; Bayraktar, S; DeAngelis, LM; Hosein, PJ; Lossos, C; Lossos, IS; Natkunam, Y; Raizer, J; Schiff, D; Sutton Posthumus, J; Tibshirani, RJ; Weinzierl, E; Younes, SF | 1 |
| Chamberlain, MC | 2 |
| Bello, C; Chavez, J; Dalia, S; Fisher, K; Forsyth, P; Jaglal, M; Lee, JH; Pan, E; Price, S; Shah, B; Sokol, L; Sotomayor, E | 1 |
| Bai, B; Cai, QC; Cai, QQ; Gao, Y; Huang, HQ; Jiang, WQ; Wang, XX; Xia, YF; Xia, ZJ | 1 |
| Cen, J; Li, C; Liu, X; Ma, Y; Mei, K; Qian, L; Shen, J; Wang, Y; Zhao, D | 1 |
| Baldini, L; Balzarotti, M; Bobbio, F; Brandes, AA; Ciceri, F; Corazzelli, G; Ferreri, AJ; Ilariucci, F; Montanari, M; Reni, M; Spina, M; Stelitano, C; Zaja, F | 1 |
| Ghose, A; Kundu, R; Latif, T | 1 |
| Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Yano, S | 1 |
| Hensel, M; Hentrich, M; Hoffmann, C; Mosthaf, F; Müller, M; Siehl, J; Wyen, C | 1 |
| Baars, JW; Boogerd, W; Brandsma, D; de Jong, D; Dewit, L; Hart, A; Kersten, MJ; Spiering, M; van Tinteren, H | 1 |
| Dalia, S; Forsyth, P; Jaglal, M; Price, S; Sokol, L | 1 |
| Fujimaki, K; Hagihara, M; Hashimoto, C; Ishibashi, D; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Kishimoto, K; Koyama, S; Motomura, S; Numata, A; Ohshima, R; Sakai, R; Tachibana, T; Taguchi, J; Takahashi, H; Takasaki, H; Takemura, S; Tomita, N; Watanabe, R | 1 |
| Abdelaziz, A; Ambady, P; Blakeley, J; Bonekamp, D; Grossman, SA; Holdhoff, M; Sarai, G; Ye, X | 1 |
| Engert, A; Kasenda, B; Skoetz, N; Zacher, J | 1 |
| Fleckenstein, J; Glass, B; Hänel, M; Held, G; Kempf, B; Mahlberg, R; Murawski, N; Pfreundschuh, M; Rübe, C; Schmitz, N; Viardot, A; Witzens-Harig, M; Zeynalova, S; Ziepert, M; Zwick, C | 1 |
| Imai, K; Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Chang, Y; Fu, XR; Han, LJ; Li, L; Li, X; Ma, W; Sun, ZC; Wang, XH; Wu, JJ; Zhang, L; Zhang, MZ; Zhang, XD | 1 |
| Chinthammitr, Y; Rujimethapass, S; Sitthinamsuwan, B; Treetipsatit, J | 1 |
| Matsushita, H; Onishi, H; Onodera, S; Shibamoto, Y; Sugie, C; Sumi, M; Takemoto, M; Tamaki, Y; Tsuchida, E | 1 |
| Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P | 1 |
| Anderson, JR; Barth, M; Cairo, MS; Frazer, JK; Galardy, P; Goldman, S; Gross, TG; Harrison, L; Perkins, SL; Sanger, W; Shiramizu, B; Smith, L; Weinstein, H | 1 |
| Burbury, K; Carney, DA; Cheah, CY; Dickinson, M; Fedele, PL; George, A; Gilbertson, M; Harrison, SJ; Herbert, KE; Januszewicz, EH; Kennedy, GA; O'Rourke, K; Opat, SS; Prince, HM; Ritchie, DS; Seymour, JF; Tam, CS; Tan, SY; Westerman, DA; Wolf, M | 1 |
| Namekawa, M | 1 |
| Birnbaum, T; Griesinger, F; Hertenstein, B; Kanz, L; Korfel, A; Kreher, S; Martus, P; Rauch, M; Röth, A; Roth, P; Strehlow, F; Thiel, E; Weller, M | 1 |
| Bruno-Ventre, M; Caligaris-Cappio, F; Citterio, G; Donadoni, G; Ferreri, AJ; Foppoli, M; Govi, S; Ponzoni, M; Sassone, M; Scarfò, L; Vignati, A | 1 |
| Boop, FA; Broniscer, A; Gajjar, A; Klimo, P; Onar-Thomas, A; Panetta, JC; Patay, Z; Qaddoumi, I; Reddick, WE; Robinson, G; Stewart, CF; Ward, D; Wright, KD | 1 |
| Cesur, M | 1 |
| Bazine, A; Bellefqih, S; Benjaafar, N; Diakité, A; El Kacimi, H; Kebdani, T; Khalil, J; Mezouri, I | 1 |
| Date, I; Ichikawa, T; Ishida, J; Kawasaki, A; Kondo, E; Kurozumi, K; Maeda, Y; Michiue, H | 1 |
| Chen, BA; Xiao, YH; Yu, ZP; Yuan, P; Yue, TH | 1 |
| Agis, H; Berghoff, AS; Bojic, M; Kalhs, P; Preusser, M; Rabitsch, W; Sperr, WR; Troch, M; Widhalm, G; Wöhrer, A | 1 |
| Abrey, LE; Baser, RE; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, CC; Kaley, TJ; Matasar, MJ; Moskowitz, CH; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Sauter, CS | 1 |
| Cohen, I | 1 |
| Bairey, O; Batchelor, TT; Bhatnagar, N; Blay, JY; Briel, M; Bromberg, J; Chiba, S; Ferlay, C; Ferreri, AJ; Forst, D; Fosså, A; Fritsch, K; Ghesquieres, H; Gloy, V; Haug, S; Hoang-Xuan, K; Illerhaus, G; Kasenda, B; Marturano, E; O'Neill, BP; Okoshi, Y; Omuro, A; Pulczynski, EJ; Rahner, S; Schandelmaier, S | 1 |
| Stewart, CF; Wright, KD | 1 |
| Neuwelt, EA; Schiff, D | 1 |
| Bamberg, M; Birnbaum, T; Fischer, L; Fischer, T; Griesinger, F; Herrlinger, U; Hertenstein, B; Hundsberger, T; Jahnke, K; Junghanß, C; Korfel, A; Martus, P; Mergenthaler, HG; Möhle, R; Pietsch, T; Rauch, M; Röth, A; Roth, P; Thiel, E; Weller, M | 1 |
| Batchelor, TT; Nayak, L; Pentsova, E | 1 |
| Bandoh, S; Dobashi, H; Imataki, O; Izumikawa, M; Kameda, T; Morimoto, H; Nakashima, S; Shimada, H; Susaki, K; Takeuchi, Y | 1 |
| Higuchi, Y; Hirono, S; Iwadate, Y; Matsutani, T; Nagano, O; Saeki, N; Serizawa, T | 1 |
| DeAngelis, LM | 1 |
| Abla, O; Di Giuseppe, G; Gupta, S; Hitzler, J; Wilejto, M | 1 |
| Abarah, W; Choquet, S; Coso, D; Damaj, G; Diouf, M; Dupuis, J; Gac, AC; Garidi, R; Ghesquières, H; Gressin, R; Houillier, C; Ivanoff, S; Marjanovic, Z; Morschhauseur, F; Parcelier, A; Soussain, C; Troussard, X; Ysaebert, L | 1 |
| Beshlawi, I; Bhuyan, D; El-Banna, N; Elmanzalawy, A; Rabah, F | 1 |
| Ahmadzadeh, A; Hajizamani, S; Jalaeikhoo, H; Keyhani, M; Rahim, F; Sadeghi Hariri, B; Saki, N; Yekaninejad, MS | 1 |
| Connors, JM; Gerrie, AS; Kansara, R; Savage, KJ; Sehn, LH; Shenkier, TN; Villa, D | 1 |
| Ambady, P; Bonekamp, D; Grossman, SA; Holdhoff, M; Wong, F | 1 |
| Abramson, JS; Cassaday, R; Chavez, JC; Fenske, TS; Gandhi, M; Jaso, J; Landsburg, DJ; Medeiros, LJ; Nabhan, C; Petrich, AM; Press, O; Shah, N; Sohani, AR; Song, K; Yang, DT; Zelenetz, AD | 1 |
| Alnahhas, I; Malkin, M | 1 |
| Ardeshna, K; Badat, M; Cheesman, S; D'Sa, S; Joshi, R; Lambert, J; Linch, D; Maciocia, P; Mohamedbhai, S; Pule, M | 1 |
| Barrié, M; Benouaich-Amiel, A; Chinot, O; Choquet, S; del Rio, MS; Delgadillo, D; Delwail, V; Ghesquieres, H; Gonzalez-Aguilar, A; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Huchet, A; Lacomblez, L; Lamy, T; Lebouvier-Sadot, S; Omuro, A; Soubeyran, P; Soussain, C; Taillandier, L; Tanguy, ML; Touitou, V | 1 |
| Akkari, L; Curry, RC; Diamond, EL; Faivre, G; Fisher, R; Joyce, JA; Lin, O; Omuro, A; Rosenblum, M | 1 |
| Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H | 1 |
| Amer, R; Baglivo, E; Bergstrom, C; Bodaghi, B; Bron, D; Caspers, LE; Chan, CC; Chaput, F; Grossniklaus, HE; Kozyreff, A; LeHoang, P; Pe'er, J; Touitou, V | 1 |
| Chang, JH; Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SH; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H; Suh, CO; Yang, WI | 1 |
| Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M | 1 |
| Cen, J; Qian, L; Shen, J; Yin, W; Zhou, C | 1 |
| Gurion, R; Hamlin, P; Horwitz, S; Lunning, M; Mehta, N; Migliacci, JC; Moskowitz, A; Moskowitz, C; Zelenetz, A | 1 |
| Bosq, J; Cartron, G; Casasnovas, O; Chassagne-Clément, C; Coiffier, B; Cornillon, J; Dombret, H; Fornecker, LM; Ghesquieres, H; Girault, S; Koscielny, S; Lamy, T; Le Gouill, S; Leguay, T; Mariette, C; Morschhauser, F; Ojeda-Uribe, M; Recher, C; Ribrag, V; Salles, G; Tilly, H; Verge, V | 1 |
| Burger, E; Ferreri, AJ; Finke, J; Fricker, H; Fritsch, K; Grishina, O; Ihorst, G; Illerhaus, G; Kasenda, B; Mikesch, K; Schorb, E; Valk, E; Zucca, E | 1 |
| Alexander, B; Hong, F; Schiff, D | 1 |
| Ambrosetti, A; Balzarotti, M; Binder, M; Cavalli, F; Cwynarski, K; Deckert, M; Fabbri, A; Ferrari, A; Ferreri, AJ; Finke, J; Fox, CP; Gørløv, JS; Hemmaway, C; Hertenstein, B; Hess, G; Illerhaus, G; Johnson, P; Keller, U; Krause, SW; Levis, A; Linton, KM; Panse, J; Pisani, F; Politi, LS; Ponzoni, M; Pukrop, T; Pulczynski, E; Reni, M; Rosée, PL; Roth, A; Rudà, R; Schmoll, HJ; Schorb, E; Stilgenbauer, S; Torri, V; Tucci, A; Zucca, E | 1 |
| Bodaghi, B; Cassoux, N; Choquet, S; Costopoulos, M; Hoang-Xuan, K; Houillier, C; Le Cossec, C; Legarf-Tavernier, M; LeHoang, P; Nguyen, DT; Omuro, A; Soussain, C; Touitou, V | 1 |
| Geng, H; Ji, LH; Luo, W; Ma, J; Ma, XJ; Xiong, H; Yin, QC; Yin, YJ; Yu, L | 1 |
| Deng, XF; Wang, XX; Zhang, Q; Zhang, Y; Zhu, YZ | 1 |
| Akiyama, H; Arai, A; Kubo, F; Miki, T; Miura, O; Mochizuki, M; Takase, H; Tomita, M; Yamamoto, M | 1 |
| Bentz, M; Binder, M; Deckert, M; Edinger, M; Egerer, G; Finke, J; Fricker, H; Frickhofen, N; Fritsch, K; Hader, C; Hau, P; Hirt, C; Ihorst, G; Illerhaus, G; Kasenda, B; Keller, U; Lamprecht, M; Möhle, R; Pfreundschuh, M; Röth, A; Schorb, E; Stilgenbauer, S; Valk, E; von Baumgarten, L; Wolf, HH | 1 |
| Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Oki, Y; Westin, JR | 1 |
| Baars, JW; Bromberg, JEC; Doorduijn, JK; Enting, RH; Kersten, MJ; Lugtenburg, PJ; MacKenzie, MA; Poortmans, P; Schaafsma, MR; Schouten, HC; Spoelstra, FM; van den Bent, MJ; van der Holt, B; van Imhoff, GW | 1 |
| Abrams, DI; Chavez, JC; Griffin, A; Gupta, NK; Hwang, J; Jaglal, M; Kaplan, LD; Luce, JA; Mannis, G; Nolan, A; Omuro, A; Reid, EG; Rubenstein, JL; Rubinstein, PG; Treseler, PA; Volberding, P; Wang, CC | 1 |
| Choi, YJ; Kim, JE; Kim, S; Kim, TW; Lee, JS; Lee, JY; Park, H; Park, JS; Suh, C; Yoon, DH | 1 |
| Nickelsen, M; Savage, KJ; Schmitz, N | 1 |
| Huang, YC; Jou, JR | 1 |
| Belhabri, A; Biron, P; Blay, JY; Chassagne-Clément, C; Ducray, F; Faurie, P; Ferlay, C; Fossard, G; Ghesquières, H; Jouanneau, E; Nicolas-Virelizier, E; Rey, P; Sebban, C; Sunyack, MP; Thiesse, P | 1 |
| DU, CY; Duan, LJ; Li, C; Yang, RY | 1 |
| Fujiwara, SI; Hatano, K; Kanda, Y; Kawasaki, Y; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Zucca, E | 1 |
| Andersson, M; Azambuja, E; Balil, A; Crown, JP; Dolci, S; Francis, P; Gelber, RD; Gnant, M; Gutierrez, J; Láng, I; Nordenskjöld, B; Pestalozzi, BC; Piccart-Gebhart, M; Quinaux, E; Viale, G | 1 |
| Abrey, LE; Ben-Porat, LS; DeAngelis, LM; Ekenel, M; Iwamoto, FM; Panageas, KS; Yahalom, J | 1 |
| Seth, R; Thavaraj, V | 1 |
| Fischer, L; Jahnke, K; Kiewe, P; Korfel, A; Neumann, M; Thiel, E | 1 |
| Batchelor, TT; Betensky, RA; Engler, DA; Gerstner, ER; Hochberg, FH; Mrugala, MM; Nierenberg, K; Nugent, W; Zhu, JJ | 1 |
| Bell, SD; Bourekas, EC; Macnealy, MW; McGregor, JM; Newton, HB; Ray Chaudhury, A; Slone, HW | 1 |
| Dölken, G; Hirt, C; Kiefer, T; Krüger, WH; Montemurro, M; Niederwieser, D; Pasold, R; Schüler, F; Schwenke, M | 1 |
| Bangard, C; Glasmacher, A; Jürgens, A; Linnebank, M; Moskau, S; Orlopp, K; Pels, H; Schlegel, U; Schmidt-Wolf, IG; Semmler, A; Simon, M; Urbach, H; Vogt-Schaden, M | 1 |
| Cai, QQ; Gao, Y; Huang, HQ; Li, S; Liao, H; Lin, XB; Xia, ZJ; Zhou, NN | 1 |
| Alonso, N; Arranz, R; Blanes, M; Conde, E; Deben, G; Fernández de Sevilla, A; Fernández-Abellán, P; Morgades, M; Nicolás, C; Ribera, JM; Rodríguez, MJ; Sánchez, E; Sancho, JM | 1 |
| Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C | 1 |
| Damek, DM; Dogan, A; Giannini, C; Kleinschmidt-DeMasters, BK; Lillehei, KO | 1 |
| Hong, JT; Hong, YK; Kim, IS; Lee, KS; Lee, SW; Son, BC; Sung, JH; Yang, SH | 1 |
| Baleydier, F; Bertrand, Y; Kebaili, K; Mialou, V; Pages, MP; Pondarre, C; Pracros, JP | 1 |
| Brown, RD; Jahnke, K; Kraemer, DF; Lewin, SJ; Muldoon, LL; Neuwelt, EA; Soussain, C; Varallyay, CG | 1 |
| Candy, S; Heckmann, JM; O'Ryan, S | 1 |
| Auger, D; Warnick, E | 1 |
| Angelov, L; Barnett, GH; Bell, S; Doolittle, ND; Ference, S; Haluska, M; Hedrick, NA; Jahnke, K; Kraemer, DF; Lacy, CA; McGregor, J; Neuwelt, EA; Peereboom, DM; Shalom, E; Siegal, T; Sorenson, L; Stevens, G; Tyson, RM | 1 |
| Bayles, A; Bowman, WP; Boyett, JM; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Handgretinger, R; Howard, SC; Jeha, S; Kaste, SC; Kun, LE; Leung, W; Metzger, ML; Onciu, M; Pei, D; Pui, CH; Raimondi, SC; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Simmons, V | 1 |
| Chang, MH; Kim, K; Kim, KH; Kim, SJ; Kim, WS; Ko, YH; Kong, DS; Lee, JI; Lim, do H; Nam, DH; Park, KW; Park, W; Uhm, JE; Yi, SY | 1 |
| Swinnen, LJ | 1 |
| Conrad, AL; Go, RS | 1 |
| Ajzenberg, C; Alonso, E; Berle, M; Caillet, P; Combes, C; Krypciak, S; Paillaud, E; Taillandier-Heriche, E | 1 |
| Aondio, GM; Avvisati, G; Balzarotti, M; Brandes, AA; Cabras, MG; Caligaris-Cappio, F; Cavalli, F; Corazzelli, G; Fabbri, A; Fajardo, J; Ferreri, AJ; Foppoli, M; Frezzato, M; Gomez, H; Guarini, A; Ilariucci, F; Martelli, M; Pangalis, GA; Picozzi, P; Pinotti, G; Ponzoni, M; Reni, M; Rigacci, L; Rossi, G; Soffietti, R; Stelitano, C; Uhlmann, C; Vallisa, D; Vezzulli, P; Zaja, F; Zoppegno, L; Zucca, E | 1 |
| O'Brien, PC; Seymour, JF | 1 |
| Cakiroglu, H; Fischer, L; Kiewe, P; Korfel, A; Pfeiffer, S; Thiel, E; Volk, HD; Widmann, T | 1 |
| Czumbil, L; Gyánó, G; Iványi, JL; Marton, E; Plander, M; Tóth, C | 1 |
| Yamanaka, R | 1 |
| Mok, MY; Trendell-Smith, NJ; Tsang, HH; Wu, AK | 1 |
| Fujimoto, H; Fukutake, K; Funato, K; Hashimoto, Y; Yotsumoto, M | 1 |
| Biron, P; Blay, JY; Bosly, A; Casasnovas, O; Coiffier, B; Colin, P; Ferlay, C; Ghesquières, H; Haioun, C; Morel, P; Perol, D; Reman, O; Sebban, C; Tilly, H; Van den Neste, E | 1 |
| Collins, C; Knoderer, H | 1 |
| Maeshima, AM; Maruyama, T; Miyakita, Y; Momota, H; Muragaki, Y; Narita, Y; Shibui, S; Shinomiya, A | 1 |
| Cobert, J; Hochberg, E; Hochberg, F; Woldenberg, N | 1 |
| Arita, N; Hashimoto, N; Izumoto, S; Kagawa, N; Kinoshita, M; Maruno, M; Ohnishi, T; Okita, Y; Yoshimine, T | 1 |
| Cavalli, F; Cerny, T; Ferreri, AJ; Huitema, AD; Joerger, M; Krähenbühl, S; Reni, M; Schellens, JH; Zucca, E | 1 |
| Manconi, FM; Mascia, MG; Milia, A; Pilia, G | 1 |
| Carrabba, MG; Chiara, A; Ciceri, F; Ferreri, AJ; Foppoli, M; Franzin, A; Politi, LS; Reni, M; Villa, E | 1 |
| Arai, A; Ishiwata, Y; Miura, O; Mochizuki, M; Nakauchi, Y; Shibata, S; Shibuya, Y; Sugita, S; Takase, H; Yasuhara, M | 1 |
| Chamberlain, MC; Johnston, SK | 1 |
| Abrey, LE | 2 |
| Abramson, JS; Barnes, JA; Hammerman, P; Hellmann, M; Hochberg, EP; Muzikansky, A; Takvorian, T; Toomey, C | 1 |
| Aiba, K; Dobashi, N; Kamiyama, Y; Machishima, T; Minami, J; Morikawa, N; Osawa, H; Otsubo, H; Saito, T; Takahara, S; Takei, Y; Usui, N; Yahagi, Y; Yamaguchi, Y; Yano, S | 1 |
| Koo, YX; Lai, GG; Lim, ST; Tan, TT; Tao, M | 1 |
| Cavalli, F; Ferreri, AJ; Illerhaus, G; Zucca, E | 1 |
| Benz-de Bretagne, I; Blasco, H; Chatelut, E; Colombat, P; Hulot, JS; Le Gouge, A; Le Guellec, C; Pinard, E; Senecal, D | 1 |
| Bromberg, JE; Doorduijn, J; Enting, R; Poortmans, P; Schuurmans, M; Seute, T; Taphoorn, MJ; van den Bent, MJ; van Imhoff, G; van Norden, Y | 1 |
| Ballman, KV; Brown, PD; Carrero, XW; Colgan, JP; Fitch, TR; Gilbert, MR; Habermann, TM; Hawkins, RB; Kurtin, PJ; Laack, NN; Morton, RF; O'Fallon, JR; O'Neill, BP; Pajon, ER; Scheithauer, BW; Windschitl, HE | 1 |
| Hilliard, LM; Kelly, DR; Nabors, LB; Oakes, WJ; Reddy, AT; Shah, AC | 1 |
| Abdelsalam, M; Akhtar, S; Al-Shabana, M; AlHusaini, H; El Weshi, A; El-Husseiny, G; Khafaga, Y; Maghfoor, I; Rahal, M | 1 |
| Catalano, P; Chen, YH; Khimani, NB; Mauch, PM; Ng, AK; Silver, B | 1 |
| Choi, CW; Kim, H; Kim, JS; Kim, SJ; Kim, WS; Lee, GW; Oh, SY; Park, J; Shin, HJ; Suh, C; Won, JH; Yang, DH | 1 |
| Chiba, S; Hasegawa, Y; Matsumura, A; Okoshi, Y; Sakamoto, N; Takano, S; Taoka, K | 1 |
| Cabanillas, F | 1 |
| Bamberg, M; Birnbaum, T; Fischer, L; Griesinger, F; Herrlinger, U; Hertenstein, B; Hundsberger, T; Jahnke, K; Kanz, L; Korfel, A; Leithäuser, M; Martus, P; Mergenthaler, HG; Nägele, T; Pietsch, T; Plasswilm, L; Rauch, M; Röth, A; Thiel, E; von Toll, T; Weller, M | 1 |
| Ellison, DW; Frobisher, C; Hawkins, MM; Lancashire, ER; Little, MP; Reulen, RC; Stiller, CA; Stovall, M; Sugden, E; Taylor, AJ; Winter, DL | 1 |
| Bessell, EM; Dickinson, P; Dickinson, S; Salmon, J | 1 |
| Durrbach, A; Fermé, C; Hanna, C; Matta, C; Moise, L; Pilorge, S; Ribrag, V | 1 |
| Fukushima, T; Hanada, R; Hasegawa, D; Ishida, Y; Kikuchi, A; Kiyokawa, N; Koh, K; Manabe, A; Ohara, A; Saito, T; Tsuchida, M | 1 |
| Finke, J; Fritsch, K; Hader, C; Haug, S; Haug, V; Ihorst, G; Illerhaus, G; Kasenda, B; Nikkhah, G; Prinz, M | 1 |
| Cohen, IJ | 2 |
| Fujii, K; Kijima, C; Miyajima, Y; Oka, H; Utsuki, S; Yasui, Y | 1 |
| Corazzelli, G; Fava, S; Ferreri, AJ; Foppoli, M; Franzin, A; Licata, G; Paolini, R; Politi, LS; Ponzoni, M; Reni, M; Stelitano, C; Zaja, F; Zucca, E | 1 |
| Abrey, LE; DeAngelis, LM; Hedvat, C; Nayak, L; Rosenblum, MK | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Joo, YD; Kim, SG; Lee, SM; Oh, SY; Seol, YM; Shin, DH; Shin, HJ; Song, MK; Yun, EY | 1 |
| Alaoui-Slimani, K; Biron, P; Blay, JY; Chassagne-Clement, C; de la Fouchardiere, A; de Prijck, B; Delannoy, A; Devidas, A; Ferlay, C; Ghesquières, H; Ketterer, N; Lepretre, S; Provencher, S; Sebban, C; Thyss, A; Tilly, H | 1 |
| Doolittle, ND; Dósa, E; Kraemer, DF; Lewin, SJ; Muldoon, LL; Neuwelt, EA; Pagel, MA | 1 |
| Al-Futaisi, A; Al-Kharusi, N; Biswas, J; Ganesh, A; Khetan, V; Kumar, K; Raja, T | 1 |
| Kim, YZ; Lee, EH; Sung, KH | 1 |
| Shimada, K | 1 |
| Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Jin, ZX; Kawanami, T; Kurose, N; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Sun, Y; Tanaka, M; Umehara, H | 1 |
| Baldi, I; Balzarotti, M; Bottelli, C; Cavalli, F; Chiappella, A; Conconi, A; Ferreri, AJ; Gomez, H; Gospodarowicz, MK; Lopez-Guillermo, A; Martelli, M; Martinelli, G; Merli, F; Novero, D; Orsucci, L; Pavone, V; Ricardi, U; Sarris, AH; Storti, S; Vitolo, U; Zucca, E | 1 |
| Graber, JJ; Omuro, A | 2 |
| Ferreri, AJ; Huitema, AD; Illerhaus, G; Joerger, M | 2 |
| Buckstein, R; Cheung, MC; Doherty, M; Gerard, LM; Imrie, KR; Mackenzie, R; Mangel, J | 1 |
| Batchelor, TT; Egerer, G; Engert, A; Herrlinger, U; Kowoll, A; Lamprecht, M; Linnebank, M; Patrij, K; Pels, H; Reiser, M; Schackert, G; Schlegel, U; Schmidt-Wolf, IG; Vogt-Schaden, M; Wätzel, L | 1 |
| Abrey, LE; Deangelis, LM; Morris, PG; Omuro, A; Panageas, KS; Reiner, AS; Seko, BS; Wu, N | 1 |
| Choquet, S; Elhallani, S; Gonzalez-Aguilar, A; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Navarro, S; Omuro, A; Ricard, D; Sierra Del Rio, M; Soussain, C | 1 |
| Blasius, E; Glas, M; Herrlinger, U; Pels, H; Schlegel, U; Steinbeck, JA; Stuplich, M | 1 |
| Hidaka, T; Ishizaki, J; Katayose, K; Kawano, H; Kawano, N; Kubuki, Y; Maeda, K; Matsuoka, H; Ochiai, H; Oshima, K; Satou, S; Shide, K; Shimao, Y; Shimoda, H; Shimoda, K; Takenaka, K; Toyama, T; Ueda, A; Yamaguchi, K; Yamashita, K; Yano, T; Yoshida, S | 1 |
| Gonzalez-Aguilar, A; Hoang-Xuan, K; Houillier, C; Soussain, C | 1 |
| Cavallin-Stahl, E; Glass, B; Haenel, M; Kaiser, U; Loeffler, M; Pfreundschuh, M; Schmitz, N; Truemper, L; Wolf, M; Zeynalova, S | 1 |
| Buck, G; Gibson, B; Halsey, C; Hill, F; Richards, S; Vargha-Khadem, F | 1 |
| Abrey, LE; Correa, DD; Deangelis, LM; Deutsch, MB; Omuro, AM; Shi, W; Thaler, HT | 1 |
| Al-Ali, HK; Busemann, C; Dölken, G; Helke, K; Herbst, R; Hirt, C; Kessler, C; Kiefer, T; Kirsch, M; Krüger, WH; Maschmeyer, G; Montemurro, M; Niederwieser, D; Schroeder, H; Schüler, F; Späth, C; Vogelgesang, S; Wolf, HH | 1 |
| Behler, CM; Cha, S; Damon, LE; Hwang, J; Issa, S; McDermott, M; O'Brien, J; Rubenstein, JL; Shuman, MA; Treseler, P; Valles, F; Wieduwilt, MJ | 1 |
| Finke, J; Franzem, M; Fritsch, K; Illerhaus, G; Kasenda, B; Lebiedz, D; Rehberg, M; Schorb, E; Thürmann, P; Veelken, H | 1 |
| Falchi, L; Ferranti, L; Gunnellini, M; Liberati, AM | 1 |
| Birnbaum, T; Stadler, EA; Straube, A; von Baumgarten, L | 1 |
| Sato, K; Uchiyama, M | 1 |
| Peereboom, DM; Xie, H | 1 |
| Chan, K; Cheung, MC; Prica, A | 1 |
| Bloomfield, CD; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Marcucci, G; McDonnell, D; Mrózek, K; Powell, BL; Stock, W; Stone, RM; Vardiman, JW; Westervelt, P; Wetzler, M | 1 |
| Bi, CF; Lin, L; Liu, WP; Luo, TY; Min, M; Wang, XQ; Zhang, WY; Zhao, S | 1 |
| Berinstein, N; Buckstein, R; Cheung, MC; Guirguis, HR; Imrie, KR; Mahrous, M; Piliotis, E; Zhang, L | 1 |
| Arita, N; Mori, K | 1 |
| Iwadate, Y | 1 |
| Kaun, S; Kiewe, P; Klasen, H; Korfel, A; Martus, P; Möhle, R; Rauch, M; Röth, A; Roth, P; Thiel, E; Weller, M | 1 |
| Deangelis, LM; Omuro, A; Welch, MR | 1 |
| Abrey, LE; Deangelis, LM; Hatzoglou, V; Karimi, S; Partovi, S; Punia, V | 1 |
| Glas, M; Herrlinger, U; Schäfer, N | 1 |
| Bangard, C; Egerer, G; Kowoll, A; Linnebank, M; Moskau, S; Pels, H; Reichmann, H; Schackert, G; Schlegel, U; Schmidt-Wolf, IG; Semmler, A; Vogt-Schaden, M | 1 |
| Bergner, N; Engert, A; Illerhaus, G; Monsef, I; Skoetz, N | 1 |
| Assanelli, A; Baldini, L; Caligaris-Cappio, F; Ferrari, A; Ferreri, AJ; Foppoli, M; Frezzato, M; Frungillo, N; Ilariucci, F; Licata, G; Mappa, S; Marturano, E; Proserpio, I; Reni, M; Sorarù, M; Stelitano, C; Vianello, F | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY; Yoon, JH | 1 |
| Birnbaum, T; Bochmann, K; Straube, A; von Baumgarten, L | 1 |
| Abrey, LE; DeAngelis, LM; Khan, RB; Shi, W; Thaler, HT | 1 |
| Korinthenberg, R; Niemeyer, C; Schneider, A | 1 |
| Doolittle, ND; Neuwelt, EA; Pe'er, J; Rosenbaum, JT; Siegal, T; Smith, JR; Wilson, DJ | 1 |
| Ishigatsubo, Y; Kanamori, H; Kodama, F; Motomura, S; Tomita, N | 1 |
| Kellie, SJ; Lockwood, L; Mauger, DC; Pozza, LD; Waters, KD; White, L; Wong, CK | 1 |
| Bürger, B; Kühl, J; Löning, L; Mann, G; Reiter, A; Riehm, H; Schrappe, M; Zimmermann, M | 1 |
| Chan, GC; Cheung, AY; Chik, KW; Ha, SY; Lee, AC; Li, CK; Ling, SC; Luk, CW; Shing, MM; Yuen, HL | 1 |
| Batchelor, TT; Betensky, RA; Braaten, KM; de Leval, L; Harris, NL; Hochberg, FH; Louis, DN; Okada, Y | 1 |
| Grossman, SA; Mathew, BS | 1 |
| Chua, SL; Januszewicz, EH; Prince, HM; Seymour, JF; Streater, J; Wolf, MM | 1 |
| Clarke, M; Gaynon, P; Hann, I; Harrison, G; Masera, G; Peto, R; Richards, S | 1 |
| Doolittle, ND; Kraemer, DF; Lacy, C; Neutwelt, EA; Siegal, T; Tyson, RM | 1 |
| Fischer, DH; Mason, JO | 1 |
| Fukushima, T; Katayama, Y; Komine, C; Watanabe, T; Yokoyama, T; Yoshino, A | 1 |
| Bogdanović, A; Colović, M; Janković, G; Kraguljac, N; Suvajdzić, N | 1 |
| Baron, B; Bogdhan, U; Chinot, O; De Beule, N; Delattre, JY; Frenay, M; Hildebrand, J; Hoang-Xuan, K; Soubeyran, P; Taillandier, L | 1 |
| Cabanillas, F; Cox, JD; Dabaja, BS; Ha, CS; Kyritsis, AP; Levin, V; McLaughlin, P; Meyers, CA; Preti, HA; Pro, B; Seabrooke, LF; Wilder, RB; Yung, WK | 1 |
| Akimoto, T; Hasegawa, M; Hayakawa, K; Ishikawa, H; Mitsuhashi, N; Nakano, T; Niibe, H; Sakurai, H; Tamaki, Y; Tamura, M | 1 |
| Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M | 1 |
| Atasoy, A; Bode, U; Deckert, M; Diehl, V; Egerer, G; Engert, A; Fimmers, R; Glasmacher, A; Helmstaedter, C; Klockgether, T; Kroschinsky, F; Pels, H; Reichmann, H; Schackert, G; Schaller, C; Schlegel, U; Schmidt-Wolf, IG; Schulz, H; Vogt-Schaden, M; Zellner, A | 1 |
| Abrey, LE; Anderson, ND; Caron, D; Correa, DD; Crump, M; DeAngelis, LM; Forsyth, P; Mason, WP; Moskowitz, CH; Nimer, SD; Paleologos, N; Stewart, D; Zelenetz, A | 1 |
| Batara, JF; Grossman, SA | 1 |
| Eden, OB; Gibson, B; Hann, I; Harrison, CJ; Hill, FG; Kinsey, S; Lilleyman, J; Mitchell, C; Richards, S | 1 |
| Bolam, S; Child, JA; Davies, JM; Gilson, D; Howard, MR; Jalihal, SS; Mackie, MJ; McVerry, BA; Moreton, P; Morgan, GJ; Parapia, LA; Smith, GM; Williams, AT | 1 |
| Ambrosetti, A; Brandes, A; Calderoni, A; Dell'Oro, S; Ferrarese, F; Ferreri, AJ; Govi, S; Gubkin, A; Guerra, E; Locatelli, M; Pasini, F; Pivnik, A; Regazzi, M; Reni, M; Rognone, A; Spina, M; Villa, E | 1 |
| Tardif, Y; Tourville, E | 1 |
| Carlsen, N; Flaegstad, T; Forestier, E; Glomstein, A; Gustafsson, G; Kristinsson, J; Lanning, M; Mellander, L; Saarinen-Pihkala, UM; Schroeder, H | 1 |
| Greenberg, ML; Hitzler, JK; Maze, R; Nathan, PC; Spiegler, B; Weitzman, S | 1 |
| Chinot, OL; Hoang-Xuan, K; Taillandier, L | 1 |
| O'Neill, BP | 1 |
| Abrey, LE; Correa, DD; DeAngelis, LM; Glass, A; Shi, W; Thaler, H | 1 |
| Bromberg, JE; Haaxma-Reiche, H; Harder, H; Holtel, H; Kluin-Nelemans, HC; Menten, J; Poortmans, P; van den Bent, MJ | 1 |
| Barcos, M; Bloomfield, CD; Canellos, GP; Johnson, JL; Larson, RA; Lee, EJ; Niedzwiecki, D; Peterson, BA; Powell, BL; Rizzieri, DA; Schiffer, CA; Vardiman, JW | 1 |
| Meyer, MA | 1 |
| Aksoy, S; Altundag, K; Elkiran, ET; Onal, IK; Tekuzman, G | 1 |
| Bujassoum, S; Lipton, JH; Rifkind, J | 1 |
| Arita, N | 1 |
| Bessell, EM; Graus, F; Lewis, SA; Lopez-Guillermo, A; Petit, J; Verger, E; Villa, S | 1 |
| Aréchiga, N; Arteaga, V; Félix, I; Guinto, G; Kovacs, K | 1 |
| Harney, J; Pope, A; Short, SC | 1 |
| Tanaka, R; Yamanaka, R | 1 |
| Ambrosetti, A; Arrigoni, G; Capello, D; Dell'Oro, S; Ferrarese, F; Ferreri, AJ; Foppoli, M; Gaidano, G; Iuzzolino, P; Orvieto, E; Pasini, F; Ponzoni, M; Reni, M; Rossi, D | 1 |
| Batchelor, TT; Betensky, RA; Chon, B; Grossman, SA; Hochberg, FH; Lesser, GJ; Nabors, LB; Plotkin, SR | 1 |
| Abrey, LE; DeAngelis, LM; Demopoulos, A; Enting, RH | 1 |
| Camilleri-Broët, S; Hoang-Xuan, K; Soussain, C | 1 |
| Birkmann, J; Brücher, J; Fischer, L; Hossfeld, DK; Jahnke, K; Kirchen, H; Korfel, A; Martus, P; Nowrousian, MR; Pasold, R; Peschel, C; Stelljes, M; Thiel, E | 1 |
| Abrey, LE; DeAngelis, LM; Omuro, AM; Yahalom, J | 1 |
| Chhanabhai, M; Connors, JM; Fairey, R; Gascoyne, RD; Hoskins, P; Klasa, R; Morris, J; O'Reilly, SE; Pickles, T; Sehn, L; Shenkier, TN; Voss, N | 1 |
| Fischer, L; Herrlinger, U; Jahnke, K; Korfel, A; Martus, P; Schmittel, A; Thiel, E; Weller, M | 1 |
| Balcerska, A; Balwierz, W; Chełmecka-Hanuszewicz, L; Chybicka, A; Cwiklińska, M; Derwich, K; Jackowska, T; Kaczmarek-Kanold, M; Kowalczyk, JR; Kołtan, A; Matysiak, M; Odój, T; Płoszyńska, A; Sońta-Jakimczyk, D; Steczowicz, M; Wachowiak, J; Wojciechowska, V; Wójtowicz, A; Wysocki, M | 1 |
| Abrey, LE; DeAngelis, LM; Koutcher, JA; Lis, E; Panageas, KS; Raizer, JJ; Xu, S; Zakian, KL | 1 |
| Kunishio, K; Matsumoto, Y; Nagao, S; Okada, M | 1 |
| Hondoh, H; Morii, K; Onda, K; Shinbo, Y; Takahashi, H; Takeuchi, S; Tamura, T; Tanaka, R; Yamanaka, R | 1 |
| Farmand, S; Fliessbach, K; Kleczar, N; Klockgether, T; Linnebank, M; Orlopp, K; Pels, H; Schlegel, U; Schmidt-Wolf, IG; Urbach, H | 1 |
| Abrey, LE; Batchelor, T; Blay, JY; Connors, JM; Ferreri, AJ; Harris, N; Jahnke, K; Neuwelt, E; O'Brien, P; O'Neill, BP; Ponzoni, M; Poortmans, P; Rubenstein, J; Shenkier, TN; Thiel, E; Tsang, R | 1 |
| Bay, A; Caksen, H; Etlik, O; Oner, AF; Yilmaz, C | 1 |
| Dichgans, J; Hebart, H; Herrlinger, U; Kanz, L; Weller, M | 1 |
| Bowles, KM; Burnet, NG; Cooke, LJ; Grant, JW; Hodson, DJ; Kläger, SL; Laing, RJ; Marcus, RE; Powell, GA; Williams, MV | 1 |
| De Meyer, G; Mennes, M; Stiers, P; Uyttebroeck, A; Van Cool, SW; Vandenbussche, E; Vercruysse, G | 1 |
| Ardeshna, KM; Burton, C; Cheung, CW; Hoskin, PJ; Linch, DC; Smith, P | 1 |
| Barton, MB; Liew, KH; O'Brien, PC; Olver, IN; Poulsen, MG; Pratt, G; Roos, DE; Trotter, GE | 1 |
| Abrey, LE; Anderson, ND; Correa, D; DeAngelis, LM; Glass, A; Mason, WP | 1 |
| Abrey, LE; Begemann, M; Lassman, AB; Malkin, MG; Panageas, KS; Raizer, JJ; Shah, GD; Shah, GG | 1 |
| Nakamura, O | 1 |
| Honda, Y; Kochi, M; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Ushio, Y | 1 |
| Akdag, I; Aker, S; Bekar, A; Dilek, K; Ersoy, A; Kahvecioglu, S | 1 |
| Evans, WE; Pui, CH | 1 |
| Buck, G; Burnett, AK; Chopra, R; Cook, L; Durrant, IJ; Franklin, IM; Goldstone, AH; Lazarus, HM; Litzow, MR; Richards, SM; Rowe, JM; Tallman, MS; Wiernik, PH | 1 |
| Blake, M; Broxson, E; Gaynon, PS; Heerema, NA; Hutchinson, R; Kelleher, JF; La, M; Lindemulder, S; Masterson, M; Matloub, Y; Nachman, J; Sather, H; Sorrell, AD; Stork, LC; Wells, LM; Yanofsky, R | 1 |
| Hauser, SL | 1 |
| Jürgens, A; Pels, H; Schlegel, U | 1 |
| Baldini, L; Balzarotti, M; Bernardi, M; Bobbio, F; Brandes, AA; Caligaris Cappio, F; Corazzelli, G; Dell'Oro, S; Ferreri, AJ; Foppoli, M; Ilariucci, F; Montanari, M; Picozzi, P; Ponzoni, M; Reni, M; Spina, M; Stelitano, C; Tosoni, A; Zaja, F | 1 |
| Fischer, L; Herrlinger, U; Jahnke, K; Korfel, A; Martus, P; Thiel, E; Weller, M | 1 |
| Bello, JL; Bethencourt, C; Deben, G; Feliu, E; Hernandez-Rivas, JM; Oriol, A; Parody, R; Ribera, JM; Rivas, C; Sancho, JM | 1 |
| Chalmers, LM; Chamberlain, M; Chowdhary, S; Green, MR; Lombardi, KM | 1 |
| Partap, S; Spence, AM | 1 |
| Derigs, G; Feuerhake, F; Finke, J; Frickhofen, N; Guttenberger, R; Ihorst, G; Illerhaus, G; Marks, R; Ostertag, C; Volk, B | 1 |
| Motl, S; Stewart, CF; Waters, CM; Zhuang, Y | 1 |
| Bay, JO; Berthou, C; Bertrand, P; Brion, A; Camilleri-Broët, S; Colombat, P; Delepine, R; Delwail, V; Desablens, B; Lamy, T; Lemevel, A; Linassier, C; Rachieru, P | 1 |
| Batchelor, T; Gerber, DE; Grossman, SA; Ye, X | 1 |
| Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Hormigo, A; Yahalom, J | 1 |
| Cagayan, MS; Lu-Lasala, LR | 1 |
| Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Erbetta, A; Fariselli, L; Fiumani, A; Gaviani, P; Giovagnoli, AR; Lamperti, E; Marras, CE; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A | 1 |
| Deangelis, LM; Iwamoto, FM | 1 |
| Agarwal, R; Arkenau, HT; Chong, G; Cunningham, D; Horwich, A; Norman, A; Sirohi, B; Trumper, M; Watkins, D; Wotherspoon, A | 1 |
| Evans, WE; Pui, CH; Relling, MV | 1 |
| Balis, FM; Bleyer, WA; Brouwers, P; Feusner, J; Hunsberger, S; Miser, J; Nathan, PC; Odom, LF; Poplack, D; Reaman, G; Sather, H; Steinberg, SM; Whitcomb, T; Wolters, PL | 1 |
| Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH | 1 |
| Forero, A; Lobuglio, A; Meredith, R; Nabors, B; Shah, JJ; Shen, S; Yester, M | 1 |
| Iijima, K; Iki, S; Kida, M; Nakasone, H; Taoka, K; Urabe, A; Usuki, K; Yoshimi, A | 1 |
| Anagnostopoulos, I; Kiewe, P; Korfel, A; Loddenkemper, C; Reinwald, M; Thiel, E | 1 |
| Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I | 1 |
| Bell, BA; Camitta, B; Carroll, AJ; Chauvenet, AR; Devidas, M; Kurtzberg, J; Linda, SB; Martin, PL; Pettenati, MJ; Pullen, J; Shuster, JJ | 1 |
| DiMaggio, C; Fahey, JB | 1 |
| Hasegawa, A; Homma, J; Onda, K; Sano, M; Shinbo, Y; Tanaka, R; Tsuchiya, N; Yajima, N; Yamanaka, R | 1 |
| Digumarti, R; Rajappa, SJ; Uppin, SG | 1 |
| Batchelor, T; Gerstner, E | 1 |
| Kaban, LB; Nissenbaum, M; Troulis, MJ | 1 |
| Homma, J; Hondoh, H; Morii, K; Onda, K; Sano, M; Shinbo, Y; Takahashi, H; Tamura, T; Tanaka, R; Tsuchiya, N; Yajima, N; Yamanaka, R | 1 |
| Abrey, LE; Mohile, NA | 1 |
| Carmichael, MG | 1 |
| Höglund, P; Jönsson, P; Schrøder, H; Seidel, H; Skärby, T; Wiebe, T | 1 |
| Li, CK; Li, VC | 1 |
| Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L | 1 |
| Karantanis, D; Lowe, VJ; Mullan, BP; Nathan, MA; O'eill, BP; Peller, PJ; Subramaniam, RM; Wiseman, GA; Witte, RJ | 1 |
| Becker, A; Bode, U; Jaehde, U; Linnebank, M; Pels, H; Schlegel, U; Vezmar, S | 1 |
| Abrey, LE; Correa, DD; DeAngelis, LM; Grant, B; Lai, RK; LaRocca, R; Raizer, JJ; Schiff, D; Shah, GD; Yahalom, J | 1 |
| Adams, H; Alyman, C; Catania, L; Jandet-Brunet, C; Neuberg, DS; Robaey, P; Romero, I; Sallan, SE; Silverman, LB; Stevenson, K; Turek, J; Waber, DP | 1 |
| Ferreri, AJ; Foppoli, M; Mazza, E; Reni, M | 1 |
| Bell, S; Doolittle, ND; Fortin, D; Jahnke, K; Knight, KR; Kraemer, DF; Muldoon, LL; Neuwelt, EA | 1 |
| Barnett, GH; Bhatia, J; Deogaonkar, A; Ebrahim, Z; Elkassabany, NM; Farag, E; Ference, S; Lotto, M; Maurtua, M; Schubert, A | 1 |
| Feuerhake, F; Finke, J; Illerhaus, G; Müller, F; Ostertag, C; Schäfer, AO | 1 |
| Baker, A; Hadzic, N; Height, S; Messahel, B; Mycroft, J; Pinkerton, CR; Pritchard-Jones, K; Taj, MM | 1 |
| Chowers, I; Frenkel, S; Pe'er, J; Shalom, E; Siegal, T; Vicuna-Kojchen, J | 1 |
| Fischer, L; Kiewe, P; Korfel, A; Martus, P; Thiel, E | 1 |
| Homma, J; Hondoh, H; Kakuma, T; Morii, K; Sano, M; Shinbo, Y; Takahashi, H; Tamura, T; Tanaka, R; Tsuchiya, N; Yajima, N; Yamanaka, R | 1 |
| Chamberlain, MC; Green, MR | 1 |
| Cortes, J; Freireich, EJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Pierce, S | 1 |
| Callans, LS; Jardines, L; Torosian, MH | 1 |
| Camitta, BM; Civin, CJ; Ganick, DJ; Kamen, BA; Lauer, SJ; Leventhal, BG; Mahoney, DH; Shuster, JJ; Steuber, CP | 1 |
| Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wojnar, J | 1 |
| Bailey, C; Chessells, JM; Richards, SM | 1 |
| Crist, WM; Hancock, ML; Hudson, M; Kun, L; Mahmoud, H; Mulhern, RK; Pui, CH; Ribeiro, RC; Rivera, GK; Sandlund, JT | 1 |
| Bouffet, E; Doz, F; Gentet, JC; Mottolese, C; Plantaz, D; Ponvert, D; Roche, H; Stephan, JL; Thyss, A; Tron, P | 1 |
| Arrighini, A; Carli, M; Cordero di Montezemolo, L; Fears, TR; Fossati Bellani, F; Garrè, ML; Guazzelli, C; Jankovic, M; Rosso, P; Terracini, B | 1 |
| Butler, RW; Finlay, JL; Hill, JM; Meyers, PA; Steinherz, PG | 1 |
| Cher, L; Glass, J; Gruber, ML; Hochberg, FH | 1 |
| Argüello, A; Barrantes, JC; Barrantes, M; García, I; Jiménez, R; Lobo-Sanahuja, F | 1 |
| Coccia, PF; Gilchrist, GS; Hammond, GD; O'Brien, RT; Sather, HN; Tubergen, DG; Waskerwitz, MJ | 1 |
| Boiardi, A; Salmaggi, A; Silvani, A | 1 |
| DeAngelis, LM; Delattre, JY; Freilich, RJ; Monjour, A | 1 |
| Cher, L; Glass, J; Harsh, GR; Hochberg, FH | 1 |
| Bertino, JR; DeAngelis, LM; Fleisher, M; Lin, S; Tong, WP | 1 |
| DaSilva, V; Dent, S; Eapen, L; Girard, A; Hugenholtz, H; Stewart, DJ | 1 |
| Barton, MB; Liew, KH; O'Brien, PC; Olver, IN; Poulsen, MG; Roos, DE; Trotter, GE; Walker, QJ | 1 |
| Kamio, M; Mochizuki, T; Sawada, N; Tanaka, S | 1 |
| Fishburne, BC; Neuwelt, EA; Rosenbaum, JT; Wilson, DJ | 1 |
| Chamberlain, MC; Kormanik, PA | 1 |
| Farese, VL; Girard, PM; Jacomet, C; Lebrette, MG; Monfort, L; Rozenbaum, W | 1 |
| Ferracini, R | 1 |
| Abrey, LE; DeAngelis, LM; Yahalom, J | 2 |
| Cherlow, JM; Gaynon, PS; Lukens, JN; Nachman, J; Sather, HN; Sensel, MG; Trigg, ME; Wolff, L | 1 |
| Cheng, AL; Hung, RL; Liu, MY; Uen, WC; Wang, CH; Yeh, KH | 1 |
| Korfel, A; Thiel, E | 1 |
| Brouwers, P; deSmet, M; Heiss, J; Jaffe, E; Kohler, D; Nussenblat, R; Patronas, N; Pearson, D; Sandor, V; Simon, R; Stark-Vancs, V; Whitcup, SM; Wittes, R | 1 |
| Boiardi, A; Broggi, G; Fariselli, L; Pozzi, A; Salmaggi, A; Silvani, A | 1 |
| Anami, K; Asami, K; Fujimoto, T; Furuyama, T; Gushiken, T; Hatae, Y; Hirota, T; Ijichi, O; Iwai, A; Kanegane, H; Katano, N; Kawano, Y; Kikuta, A; Koizumi, S; Mimaya, J; Miyake, M; Mugishima, H; Nishi, K; Nishikawa, K; Sekine, I; Takeda, T; Tsurusawa, M; Watanabe, A; Yamamoto, Y; Yatabe, M | 1 |
| Damek, D; Guha-Thakurta, N; Hochberg, FH; Pollack, C | 1 |
| Bang, YJ; Ha, SW; Huh, DS; Kim, IH; Park, CI; Wu, HG | 1 |
| Filatov, LB; Konstantinova, TS; Shalaev, VA | 1 |
| Abramov, A; Attias, D; Ballin, A; Burstein, Y; Cividalli, G; Rechavi, G; Sharon, R; Stark, B; Sthoeger, D; Zaizov, R | 1 |
| Barton, M; Liew, K; O'Brien, P; Olver, I; Poulsen, M; Pratt, G; Roos, D; Trotter, G | 1 |
| Hattori, T; Matsuda, M; Seki, S; Tabata, K | 1 |
| Bode, U; Deckert-Schlüter, M; Fischer, HP; Glasmacher, A; Kleinschmidt, R; Oehring, R; Pels, H; Schlegel, U | 1 |
| Cairo, MS; Finlay, JL; Gururangan, S; Meadows, AT; Sposto, R | 1 |
| Hori, S; Kawashima, H; Mori, T; Morikawa, N; Takeyama, M | 1 |
| Abe, T; Hori, S; Kawashima, H; Mori, T; Morikawa, N; Takeyama, M | 1 |
| Attal, M; Besson, C; Brière, J; Haioun, C; Lederlin, P; Lepage, E; Reyes, F; Rose, C; Simon, D; Sonet, A; Thieblemont, C; Tilly, H | 1 |
| Al Bahrani, B; Delaney, G; Henderson, C | 1 |
| Ferreri, AJ; Reni, M; Villa, E | 1 |
| Holen, A; Moe, PJ | 1 |
| Arnold, R; Bartram, CR; Böhme, A; Freund, M; Ganser, A; Gökbuget, N; Hoelzer, D; Kneba, M; Langer, W; Lipp, T; Ludwig, WD; Maschmeyer, G; Messerer, D; Rieder, H; Thiel, E; Weiss, A | 1 |
| Garcia-Manero, G; Kantarjian, HM | 1 |
| Bamberg, M; Brugger, W; Dichgans, J; Herrlinger, U; Kanz, L; Kortmann, RD; Schabet, M; Weller, M | 1 |
| Achour, E; Azar, N; Belanger, C; Cassoux, N; Delattre, JY; Gerber, S; Hoang-Xuan, K; Leblond, V; Levy, V; Ribrag, V; Soussain, C; Suzan, F | 1 |
| Bernardi, M; Camba, L; Ciceri, F; Dell'Oro, S; Ferreri, AJ; Ponzoni, M; Reni, M; Spina, M; Terreni, MR; Tomirotti, M; Villa, E | 1 |
| Ashley, D; Cher, L; Ng, S; Rosenthal, MA | 1 |
| Bessell, EM; Byrne, P; Graus, F; Holland, I; López-Guillermo, A; Petit, J; Verger, E; Villá, S | 1 |
| Bode, U; Deckert, M; Fimmers, R; Fliessbach, K; Glasmacher, A; Helmstaedter, C; Kleinschmidt, R; Klockgether, T; Pels, H; Schlegel, U; Schmidt-Wolf, I; Van Roost, D | 1 |
| DeAngelis, LM; Gijtenbeek, JM; Rosenblum, MK | 1 |
| Batchelor, T; Kaufman, D; Leahy, N | 1 |
| Ferreri, AJ; Reni, M | 1 |
| Finke, J; Korfel, A; Schmidt-Wolf, I; Thiel, E | 1 |
| Bessell, EM; Byrne, P; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B; Petit, J; Verger, E; Villá, S | 1 |
| Bamberg, M; Benöhr, C; Brugger, W; Deckert, M; Dichgans, J; Engel, C; Herrlinger, U; Kanz, L; Kortmann, RD; Krauseneck, P; Küker, W; Meisner, C; Mergenthaler, HG; Schabet, M; Schmeck-Lindenau, HJ; Weller, M; Wiestler, OD | 1 |
| Bokstein, F; Lossos, A; Lossos, IS; Siegal, T | 1 |
| Casanova, M; Cefalo, GS; Collini, P; Ferrari, A; Fossati-Bellani, F; Gasparini, M; Luksch, R; Massimino, M; Polastri, D; Spreafico, F; Terenziani, M | 1 |
| Basso, U; Brandes, AA | 1 |
| Andrykowski, MA; Brady, MJ; Gregg, ME; Henslee-Downey, PJ; Lamb, DG; Schmitt, FA | 1 |
| Hann, IM | 1 |
| Akiyama, Y; Asato, R; Ito, M; Konishi, J; Kubota, M; Mikawa, H; Miki, Y; Okumura, R | 1 |
| Horoupian, DS; Page, KA; Vogel, H | 1 |
| Borowitz, MJ; Crist, WM; Falletta, JM; Foreman, E; Patterson, R; Pullen, DJ; Shuster, JJ; Vietti, TJ; Wharam, M | 1 |
| García Zueco, JC; López Gómez, L; Martín Guerrero, Y; Torres Gómez, M | 1 |
| Mead, GM; Sweetenham, JW; Whitehouse, JM | 1 |
| Cervos-Navarro, J; Dienemann, D; Jautzke, G; Langford, A; Pohle, HD; Ruf, B; Schürmann, D; Stein, H | 1 |
| Ablin, AR; Halberg, F; Kramer, JH; Moore, IM; Wara, W | 1 |
103 review(s) available for methotrexate and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neurotoxicity Syndromes; Prognosis | 2021 |
Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas.
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, T-Cell, Peripheral; Methotrexate; Prognosis | 2021 |
Primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Tumor Microenvironment | 2022 |
Primary Central Nervous System Lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Stem Cell Transplantation | 2022 |
Managing therapy-associated neurotoxicity in children with ALL.
Topics: Adolescent; Antibodies, Bispecific; Anticonvulsants; Antineoplastic Agents; Central Nervous System Neoplasms; Disease Management; Female; Glucocorticoids; Humans; Immunotherapy, Adoptive; Leukemia; Male; Methotrexate; Neurotoxicity Syndromes | 2021 |
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Transplantation, Autologous | 2022 |
Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Consensus; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Randomized Controlled Trials as Topic | 2022 |
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Central Nervous System Neoplasms; Child; Humans; Injections, Spinal; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies | 2022 |
Central Nervous System Lymphoma: Novel Therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local | 2022 |
Advances in therapeutic strategies for primary CNS B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, B-Cell; Methotrexate; Transplantation, Autologous | 2022 |
The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Network Meta-Analysis; Prospective Studies; Rituximab; Vincristine | 2022 |
Optimum Methotrexate Exposure in Patients With Suspected or Confirmed CNS Invasive Hematological Malignancies: A Systematic Critical Review.
Topics: Adult; Central Nervous System Neoplasms; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2023 |
CNS prophylaxis for diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local | 2022 |
Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasms, Second Primary; Rituximab | 2022 |
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Consensus; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Positron Emission Tomography Computed Tomography; Retinal Neoplasms; Rituximab; Transplantation, Autologous; Vitreous Body | 2022 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lenalidomide; Lymphoma, Non-Hodgkin; Methotrexate; Nivolumab; Pemetrexed; Procarbazine; Prospective Studies; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab; Temozolomide; Thiotepa; Vincristine | 2022 |
Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine | 2022 |
Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comorbidity; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Retrospective Studies | 2023 |
Prevention and management of secondary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies | 2023 |
CNS prophylaxis in aggressive B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Rituximab | 2022 |
Central Nervous System Prophylaxis and Treatment in Acute Leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Leukemia, Myeloid, Acute; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Vincristine | 2023 |
Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis.
Topics: Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Prospective Studies; Retinal Neoplasms; Vitreous Body | 2023 |
Review of rituximab in primary CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Rituximab | 2020 |
Advances and challenges in the treatment of primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Stem Cell Transplantation | 2020 |
[Primary central nervous system lymphomas].
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prognosis | 2020 |
Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System; Central Nervous System Neoplasms; Cranial Irradiation; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Consolidation Treatment for Primary Central Nervous System Lymphoma: Which Modality for Whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2021 |
Central Nervous System Lymphomas.
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Tumor Microenvironment | 2020 |
High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Remission Induction; Treatment Outcome | 2021 |
Current progress and future perspectives of research on intravascular large B-cell lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell Cycle Checkpoints; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Female; Forecasting; Heterografts; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Transplantation; Prednisone; Programmed Cell Death 1 Ligand 2 Protein; Progression-Free Survival; Rituximab; Vascular Neoplasms; Vincristine | 2021 |
Current management of primary central nervous system lymphoma.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Molecular Targeted Therapy; Rituximab | 2017 |
Primary Central Nervous System Lymphoma.
Topics: Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Stem Cell Transplantation | 2017 |
Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Blood-Brain Barrier; Central Nervous System Neoplasms; Cranial Irradiation; Humans; Lymphoma; Methotrexate; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Thiotepa | 2017 |
Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies.
Topics: Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Models, Neurological; Neoplasm Recurrence, Local; Rituximab; Secondary Prevention | 2017 |
Central Nervous System Involvement in Peripheral T Cell Lymphoma.
Topics: Autografts; Central Nervous System Neoplasms; Humans; Incidence; Lymphoma, T-Cell, Peripheral; Methotrexate; Stem Cell Transplantation | 2018 |
Updates on Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Methotrexate; Randomized Controlled Trials as Topic | 2018 |
Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.
Topics: Central Nervous System Neoplasms; Cranial Irradiation; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Transplantation, Autologous | 2018 |
Neuromeningeal prophylaxis for diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoprevention; Humans; Incidence; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Risk Factors | 2017 |
How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Patient Selection; Prednisone; Risk Factors; Rituximab; Vincristine | 2018 |
Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Vincristine | 2018 |
Improving outcomes in primary CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate | 2018 |
Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas?
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Radiotherapy | 2018 |
Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Cytoreduction Surgical Procedures; Humans; Immunocompromised Host; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Methotrexate; Neoplasm Staging; Neurosurgical Procedures; Prognosis; Rituximab; Survival Rate | 2019 |
Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Killer Cells, Natural; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Methotrexate; Prognosis; T-Lymphocytes | 2019 |
Primary central nervous system lymphoma: Novel precision therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Methotrexate; Molecular Targeted Therapy; Precision Medicine; Therapies, Investigational | 2019 |
Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Risk Factors; Stem Cell Transplantation; Treatment Outcome | 2019 |
[High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review].
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Rituximab | 2013 |
Development of JAK2V617F-positive polycythemia vera after chemotherapy-induced remission of primary central nervous system diffuse large B cell non-Hodgkin's lymphoma: a case report and review of the literature.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Humans; Janus Kinase 2; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Mutation, Missense; Polycythemia Vera | 2013 |
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Humans; Lymphoma; Methotrexate; Phenotype; Tumor Microenvironment | 2014 |
LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; DNA-Binding Proteins; Humans; Kaplan-Meier Estimate; LIM Domain Proteins; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Proteins; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Treatment Outcome | 2014 |
Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Rituximab; Survival Analysis; Vincristine | 2014 |
The role of additional radiotherapy for primary central nervous system lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Early Termination of Clinical Trials; Humans; Lymphoma; Methotrexate; Randomized Controlled Trials as Topic | 2014 |
[Malignant lymphoma in the central nervous system: overview].
Topics: Blood-Brain Barrier; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Positron-Emission Tomography | 2014 |
[Primary central nervous lymphoma: what is the role for radiotherapy?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Stem Cell Transplantation | 2014 |
Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2015 |
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Prognosis; Survival Rate | 2015 |
Primary CNS lymphoma and neurologic complications of hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Hematologic Neoplasms; Humans; Leukemia; Lymphoma; Methotrexate | 2015 |
Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When?
Topics: Central Nervous System Neoplasms; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate | 2016 |
Extranodal lymphoma: a reappraisal.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasm Staging; Prednisone; Prospective Studies; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Testicular Neoplasms; Treatment Outcome; Vincristine | 2008 |
Primary central nervous system lymphoma: recent progress, many remaining questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Rituximab | 2009 |
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood-Testis Barrier; Bone Marrow; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Orchiectomy; Prednisone; Radiotherapy, Adjuvant; Remission Induction; Rituximab; Salvage Therapy; Testicular Neoplasms; Transplantation Conditioning; Treatment Failure; Vincristine | 2009 |
[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Rituximab; Salvage Therapy; Temozolomide; Topotecan | 2009 |
Treatment approaches for primary CNS lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Lymphoma; Methotrexate; Prognosis; Radiotherapy; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2010 |
[Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prednisolone; Rituximab; Vascular Neoplasms; Vincristine | 2011 |
Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?
Topics: Central Nervous System Neoplasms; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Stem Cell Transplantation | 2011 |
[Management of primary central nervous system lymphoma].
Topics: Adult; Aged; Aging; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Prognosis | 2011 |
Primary central nervous system lymphoma: is there still a role for radiotherapy?
Topics: Antimetabolites, Antineoplastic; Cell- and Tissue-Based Therapy; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2011 |
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Treatment Outcome | 2012 |
Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Decision Support Techniques; Humans; Infant; Life Expectancy; Lymphoma; Markov Chains; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quality-Adjusted Life Years; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Vincristine; Young Adult | 2012 |
Primary CNS lymphoma: a clinician's guide.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Diagnosis, Differential; Evidence-Based Medicine; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Methotrexate; Prognosis | 2012 |
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Randomized Controlled Trials as Topic | 2012 |
Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Central Nervous System Neoplasms; Drug Interactions; HIV Seronegativity; Humans; Lymphoma; Methotrexate; Middle Aged; Pneumonia, Pneumocystis; Radiotherapy | 2003 |
CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Injections, Spinal; Male; Methotrexate; Multicenter Studies as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2003 |
Primary central nervous system lymphomas.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Humans; Immunocompromised Host; Lymphoma, B-Cell; Methotrexate; Radiotherapy; Survival Rate; Treatment Outcome | 2003 |
Treatment of primary central nervous system lymphoma in the elderly.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dementia; Humans; Lymphoma; Methotrexate; Middle Aged; Neurotoxicity Syndromes; Survival Rate | 2003 |
[Primary central nervous system lymphoma: diagnosis, management and current topics].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Humans; Immunocompetence; Lymphoma; Methotrexate; Nervous System Diseases; Radiotherapy Dosage | 2004 |
Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.
Topics: Central Nervous System Neoplasms; Child; Humans; Leucovorin; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2004 |
Primary central nervous system lymphomas in immunocompetent patients.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, T-Cell; Magnetic Resonance Imaging; Methotrexate | 2004 |
Advances for the treatment of primary central nervous system lymphoma (review).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Quality of Life; Recurrence; Time Factors; Treatment Outcome | 2004 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Eye Neoplasms; Female; Humans; Immunotherapy; Life Tables; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Recent advances in primary CNS lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Radiotherapy, Adjuvant | 2004 |
Controversies in primary CNS lymphoma.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate | 2005 |
[Treatment of central nervous system malignant lymphoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; HIV Infections; Humans; Lymphoma; Methotrexate | 2005 |
Treatment of acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Child; Combined Modality Therapy; Dexamethasone; Gene Expression Profiling; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2006 |
Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Humans; Lymphoma; Methotrexate; Treatment Outcome | 2006 |
Pharmacokinetic considerations in the treatment of CNS tumours.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Central Nervous System Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation, Preclinical; Humans; Methotrexate | 2006 |
An update on therapy of primary central nervous system lymphoma.
Topics: Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Survival Rate | 2006 |
High-dose methotrexate and primary central nervous system lymphoma.
Topics: Antimetabolites, Antineoplastic; Biopsy; Central Nervous System Neoplasms; Drug Administration Schedule; Drug Monitoring; Female; Humans; Incidence; Infection Control; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Nursing Assessment; Patient Care Planning; Rare Diseases; Stereotaxic Techniques; Survival Rate; Treatment Outcome | 2007 |
Primary CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Central Nervous System Neoplasms; Combined Modality Therapy; HIV Infections; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Methotrexate; Prognosis; Radiotherapy; Stem Cell Transplantation | 2007 |
Primary central nervous system lymphoma.
Topics: Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Brain; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Remission Induction; Survival Rate | 2007 |
[Optimal central nervous system directed therapy in childhood acute lymphoblastic leukemia.].
Topics: Central Nervous System; Central Nervous System Neoplasms; Child; Child, Preschool; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2007 |
Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Drug Therapy; Humans; Lymphoma; Methotrexate; Salvage Therapy; Stem Cell Transplantation; Treatment Failure | 2007 |
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mastectomy; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Radiotherapy; Soft Tissue Neoplasms | 1993 |
[Primary malignant non-Hodgkin's lymphomas of the central nervous system in immunocompetent patients: diagnostic, prognostic and therapeutic criteria].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Diagnostic Imaging; Female; Humans; Immunocompetence; Immunophenotyping; Incidence; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Radioisotope Teletherapy; Survival Analysis | 1997 |
Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Humans; Injections, Spinal; Lymphoma; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis | 2000 |
High-dose methotrexate in childhood all.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Disease-Free Survival; Drug Administration Schedule; Humans; Infusions, Intravenous; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quality of Life; Time Factors | 2000 |
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Germany; Humans; Immunophenotyping; Injections, Spinal; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Models, Theoretical; Multicenter Studies as Topic; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Risk; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2000 |
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Immunization, Passive; Immunophenotyping; Infusions, Intravenous; Injections, Spinal; Karyotyping; Mercaptopurine; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Risk; Rituximab; Survival Analysis; Texas; Treatment Outcome; Vincristine | 2000 |
Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine | 2001 |
Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Quality of Life; Risk Factors; Survival Analysis | 2002 |
CNS-directed therapy in childhood acute lymphoblastic leukaemia.
Topics: Central Nervous System Neoplasms; Child; Child, Preschool; Female; Humans; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy | 1992 |
128 trial(s) available for methotrexate and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Retrospective Studies | 2021 |
Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
Topics: Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; gamma-Glutamyl Hydrolase; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Recombinant Proteins | 2022 |
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Quality of Life; Rituximab; Thiotepa; Transplantation, Autologous | 2022 |
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Quality of Life; Remission Induction; Thiotepa; Transplantation, Autologous | 2022 |
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
Topics: Antineoplastic Agents, Alkylating; Brain; Central Nervous System Neoplasms; Disease-Free Survival; Humans; Lymphoma; Methotrexate; Temozolomide | 2023 |
Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Lymphoma; Methotrexate; Multicenter Studies as Topic; Prospective Studies; Rituximab; Treatment Outcome; Vincristine | 2023 |
Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Rituximab; Transplantation, Autologous; Vincristine | 2023 |
Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Cytarabine; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Retrospective Studies; Risk Assessment; Survival Rate | 2020 |
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Rituximab; Vincristine | 2020 |
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Central Nervous System Neoplasms; Drug Therapy, Combination; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Rituximab; Survival Rate | 2020 |
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Injections, Intraventricular; Karnofsky Performance Status; Lymphoma; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Survival Analysis | 2020 |
Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Venous Thromboembolism | 2021 |
MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Mental Status and Dementia Tests; Methotrexate; Middle Aged; Neurosurgical Procedures; Prognosis; Risk Factors; Rituximab | 2021 |
A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Rituximab; Survival Rate | 2017 |
[Curative Efficacy of High Dose MTX Combined with Rituxan for Treatment Primary CNS Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Rituximab; Treatment Outcome | 2017 |
A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcom
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Quality of Life; Treatment Outcome | 2018 |
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Survival Rate | 2018 |
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Proto-Oncogene Proteins c-bcl-6; Teniposide; Treatment Outcome; Young Adult | 2018 |
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Circulating Tumor DNA; Female; Humans; Lymphoma; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Young Adult | 2019 |
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Rituximab; Young Adult | 2019 |
Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Survival Rate | 2019 |
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Central Nervous System Neoplasms; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Rate; United Kingdom | 2019 |
Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Europe; Follow-Up Studies; Humans; Japan; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Survival Rate | 2013 |
Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Cyclophosphamide; Disease-Free Survival; Female; Humans; Injections, Spinal; Male; Methotrexate; Neoplasm Staging; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2013 |
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Rituximab; Time; Treatment Outcome; Vincristine | 2013 |
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Disease-Free Survival; Facial Neoplasms; Female; Germany; Humans; Injections, Spinal; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Radiotherapy; Rituximab; Skull Neoplasms; Survival Rate | 2014 |
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Immunocompetence; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Palliative Care; Prednisolone; Recurrence; Remission Induction; Renal Insufficiency; Thrombocytopenia; Treatment Outcome; Vindesine | 2014 |
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Central Nervous System Neoplasms; Child; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Genes, myc; Humans; Immunotherapy; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, B-Cell; Maintenance Chemotherapy; Male; Methotrexate; Prednisone; Remission Induction; Rituximab; Typhlitis; Vincristine | 2014 |
Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Drug; Eye Diseases; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Young Adult | 2015 |
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Vincristine | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Procarbazine; Prognosis; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Vincristine; Young Adult | 2015 |
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome | 2015 |
Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Combined; Anthracyclines; Autografts; Central Nervous System Neoplasms; Consolidation Chemotherapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2015 |
Journal Club: Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
Topics: Antineoplastic Agents; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate | 2015 |
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Prospective Studies; Quality of Life; Temozolomide; Treatment Outcome; Vincristine | 2015 |
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Rituximab; Temozolomide; Whole-Body Irradiation; Young Adult | 2016 |
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Humans; Idarubicin; Immunotherapy; Injections, Spinal; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Rituximab; Treatment Outcome; Young Adult | 2016 |
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; France; Humans; Hydrocortisone; Injections, Intravenous; Male; Methotrexate; Methylprednisolone; Middle Aged; Neoplasm Staging; Odds Ratio; Patient Selection; Prednisone; Proportional Hazards Models; Rituximab; Treatment Outcome; Vincristine | 2016 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous | 2016 |
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comparative Effectiveness Research; Cytarabine; Death, Sudden; Denmark; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Germany; Heart Injuries; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Induction Chemotherapy; Infections; Intraocular Lymphoma; Italy; Kaplan-Meier Estimate; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Mucositis; Neurotoxicity Syndromes; Neutropenia; Optic Nerve Neoplasms; Poisoning; Radiotherapy, Adjuvant; Remission Induction; Rituximab; Stroke; Switzerland; Thiotepa; Thrombocytopenia; Thrombosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; United Kingdom | 2016 |
Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cerebellum; Cytarabine; Dacarbazine; Eye Neoplasms; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Survival Analysis; Temozolomide; Vincristine | 2016 |
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].
Topics: Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Quality of Life; Rituximab; Survival Rate; Treatment Outcome | 2016 |
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Young Adult | 2016 |
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Rituximab; Transplantation, Autologous; Young Adult | 2017 |
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Failure | 2008 |
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukopenia; Lomustine; Longitudinal Studies; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Procarbazine; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2009 |
Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; STAT6 Transcription Factor | 2009 |
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Daunorubicin; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Infant; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Risk Factors; Secondary Prevention; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Proportional Hazards Models; Remission Induction; Treatment Outcome | 2009 |
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Societies, Medical; Time Factors; Vincristine; Young Adult | 2010 |
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Central Nervous System Neoplasms; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; International Cooperation; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 2010 |
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Prospective Studies; Rituximab; Survival Rate; Young Adult | 2010 |
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Radiotherapy Dosage; Remission Induction; Vincristine | 2011 |
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chi-Square Distribution; Cranial Irradiation; Cytarabine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Germany; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dose-Response Relationship, Drug; Feasibility Studies; Follow-Up Studies; Humans; Immunosuppression Therapy; Lymphoma; Methotrexate; Middle Aged; Organ Transplantation; Recurrence; Remission Induction; Transplantation; Treatment Outcome | 2011 |
The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System Neoplasms; Child; Child, Preschool; Cohort Studies; Cytarabine; Female; Humans; Infant; Injections, Spinal; Male; Methotrexate; Neoplasm Recurrence, Local; Netherlands; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prospective Studies; Remission Induction; Spinal Puncture; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Methotrexate; Pilot Projects; Procarbazine; Rituximab; Survival Analysis | 2011 |
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Staging; Pilot Projects; Salvage Therapy; Survival Rate; Thiotepa | 2011 |
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Testicular Neoplasms; Treatment Outcome; Vincristine | 2011 |
High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Female; Humans; Methotrexate; Middle Aged; Procarbazine; Remission Induction; Survival Rate; Vincristine | 2011 |
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Karnofsky Performance Status; Male; Methotrexate; Middle Aged; Procarbazine; Prognosis; Rituximab; Survival Analysis; Vincristine | 2011 |
The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Child, Preschool; Female; Humans; Infant; Intelligence; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2011 |
Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Lymphoma; Male; Methotrexate; Middle Aged; Quality of Life; Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cytarabine; Dacarbazine; Diffusion Magnetic Resonance Imaging; Etoposide; Female; Humans; Immunotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Rituximab; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate; Young Adult | 2013 |
Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Topics: Age Factors; Aged; Antimetabolites; Central Nervous System Neoplasms; Combined Modality Therapy; Confidence Intervals; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Watchful Waiting | 2012 |
Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain; Central Nervous System Neoplasms; Child; Child, Preschool; Electroencephalography; Female; Humans; Infant; Injections, Intravenous; Injections, Spinal; Leucovorin; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2002 |
Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Humans; Infant; Male; Medulloblastoma; Methotrexate; Neoplasms, Germ Cell and Embryonal; Prognosis; Treatment Outcome | 2002 |
Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cerebrospinal Fluid; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Female; Humans; Infant; Infant, Newborn; Injections, Spinal; Leukocyte Count; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Risk Factors; Spinal Puncture; Treatment Outcome | 2003 |
Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Treatment Outcome; Vincristine | 2003 |
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Belgium; Biopsy, Needle; Central Nervous System Neoplasms; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Spinal; Lomustine; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Multivariate Analysis; Neoplasm Staging; Probability; Procarbazine; Research; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Bromodeoxyuridine; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Infusions, Intravenous; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome | 2003 |
Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Central Nervous System Neoplasms; Cranial Irradiation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Radiotherapy Dosage; Retrospective Studies; Spinal Cord; Survival Rate; Treatment Outcome | 2003 |
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Humans; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Prospective Studies; Survival Analysis; Teniposide; Treatment Outcome | 2003 |
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisolone; Survival Analysis; Treatment Outcome | 2003 |
Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Disease-Free Survival; Humans; Infant; Leukocyte Count; Methotrexate; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2004 |
The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Idarubicin; Lymphoma; Male; Methotrexate; Middle Aged; Pilot Projects; United Kingdom | 2004 |
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Area Under Curve; Central Nervous System Neoplasms; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies | 2004 |
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Female; Humans; Leucovorin; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Survival Rate; Treatment Outcome | 2005 |
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Injections, Spinal; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Prospective Studies; Survival Rate; Thiotepa; Treatment Outcome | 2005 |
High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Glomerular Filtration Rate; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome | 2005 |
Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.
Topics: Antineoplastic Agents; Attention; Central Nervous System Neoplasms; Child; Cognition Disorders; Contraindications; Female; Humans; Injections, Spinal; Male; Mental Processes; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psychological Tests; Radiotherapy; Survivors | 2005 |
Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Ataxia; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Humans; Lymphoma; Methotrexate; Middle Aged | 2006 |
Systemic high-dose intravenous methotrexate for central nervous system metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoplasms, Unknown Primary; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
Topics: Adolescent; Adult; Asparaginase; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate | 2006 |
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemi
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Central Nervous System; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Hydrocortisone; Injections, Spinal; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Sex Factors; T-Lymphocytes; Testicular Neoplasms; Time Factors | 2006 |
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Hematologic Diseases; Humans; Idarubicin; Life Tables; Lymphoma, Non-Hodgkin; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Remission Induction; Stroke; Survival Analysis; Thiotepa | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Cytarabine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Topics: Adult; Aged; Central Nervous System Neoplasms; Creatinine; Female; Humans; Kidney Function Tests; Lymphoma; Male; Metabolic Clearance Rate; Methotrexate; Middle Aged; Retrospective Studies | 2007 |
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P.
Topics: Adolescent; Adult; Central Nervous System Neoplasms; Child; Child, Preschool; Cognition; Female; Humans; Infant; Male; Methotrexate; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Treatment Outcome | 2006 |
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Thiotepa | 2007 |
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Cell Lineage; Central Nervous System Neoplasms; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Infusions, Intravenous; Injections, Intramuscular; Injections, Spinal; Male; Mercaptopurine; Methotrexate; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2007 |
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Humans; Immunotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Pilot Projects; Procarbazine; Rituximab | 2007 |
Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Prednisone; Procarbazine; Retrospective Studies; Salvage Therapy; Survival Analysis; Vincristine | 2007 |
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2007 |
Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Brain Chemistry; Central Nervous System Neoplasms; Cytarabine; Excitatory Amino Acids; Female; Homocysteine; Humans; Injections, Intravenous; Injections, Intraventricular; Lymphoma; Male; Methotrexate; Middle Aged; Neurotoxicity Syndromes; Pilot Projects; S-Adenosylmethionine; Statistics, Nonparametric; Time Factors | 2007 |
Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Central Nervous System Neoplasms; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Female; Glucocorticoids; Humans; Hydrocortisone; Infant; Injections, Spinal; Male; Methotrexate; Neuropsychological Tests; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2007 |
Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Etoposide; Female; Humans; Infant; Infusions, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasms, Germ Cell and Embryonal; Prospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Longitudinal Studies; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Renal dysfunction during and after high-dose methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Control Studies; Central Nervous System Neoplasms; Creatinine; Dose-Response Relationship, Drug; Female; gamma-Glutamyl Hydrolase; Humans; Kidney; Kidney Diseases; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Central Nervous System Neoplasms; Child; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Injections, Spinal; Male; Mercaptopurine; Methotrexate; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 1995 |
Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain; Central Nervous System; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Infant; Injections, Spinal; Leukocyte Count; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Sex Factors; Survival Rate; Treatment Outcome; United Kingdom | 1995 |
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Cognition Disorders; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Humans; Infant; Male; Medulloblastoma; Methotrexate; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Analysis | 1995 |
Stage III abdominal non-Hodgkin's lymphoma in Costa Rican children: comparison of two consecutive trials of treatment.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Costa Rica; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Infusions, Intravenous; Leucovorin; Life Tables; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 1994 |
Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
Topics: Adolescent; Adult; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Infant; Injections, Spinal; Life Tables; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Survival Analysis | 1993 |
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Eye Neoplasms; Female; Follow-Up Studies; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Thiotepa; Tomography, X-Ray Computed; Vincristine | 1996 |
PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Mechlorethamine; Methotrexate; Middle Aged; Neurologic Examination; Prednisone; Procarbazine; Steroids; Survival Analysis; Vincristine | 1996 |
Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Australia; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Humans; Infusions, Intravenous; Lymphoma; Methotrexate; New Zealand; Prospective Studies; Survival Rate | 1996 |
Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS.
Topics: Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Injections, Intravenous; Karnofsky Performance Status; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Pilot Projects; Prospective Studies | 1997 |
Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Infant; Injections, Spinal; Male; Methotrexate; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Survival Analysis | 1998 |
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Leucovorin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Pilot Projects; Thiotepa; Vincristine | 1998 |
Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infant; Injections, Spinal; Japan; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Treatment Outcome | 1999 |
Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Remission Induction; Surveys and Questionnaires; Survival Analysis | 1999 |
Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Procarbazine; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Treatment Failure; Vincristine | 1999 |
[Prevention of neuroleukemia by intrathecal administration of cytosar and methotrexate in acute lymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Humans; Immunophenotyping; Injections, Spinal; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors; Treatment Outcome | 1999 |
Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Cytarabine; Female; Humans; Hydrocortisone; Infant; Injections, Spinal; Israel; Life Tables; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Risk; Treatment Outcome | 2000 |
Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Methotrexate; Middle Aged; Patient Compliance; Survival Analysis | 2000 |
Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Infant; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Treatment for primary CNS lymphoma: the next step.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Nervous System Diseases; Procarbazine; Radiation Injuries; Survival Analysis; Vincristine | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Salvage Therapy; Thiotepa | 2001 |
CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Survival Rate; Vincristine | 2001 |
Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Diseases; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Radiotherapy Dosage; Spain; Survival Rate; United Kingdom; Vincristine | 2002 |
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease-Free Survival; Humans; Lymphoma; Methotrexate; Middle Aged; Multivariate Analysis; Prospective Studies; Treatment Outcome | 2002 |
Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2002 |
Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System Neoplasms; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Injections, Spinal; Male; Methotrexate; Palliative Care; Prognosis; Risk Factors; Treatment Outcome; Vincristine | 2002 |
Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Erythrocytes; Female; Humans; Hydrocortisone; Infant; Injections, Spinal; Leukemia-Lymphoma, Adult T-Cell; Male; Methotrexate; Prednisone; Recurrence; Remission Induction; Rosette Formation; Thioguanine; Treatment Outcome; Vincristine | 1992 |
364 other study(ies) available for methotrexate and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult | 2022 |
Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.
Topics: Central Nervous System Neoplasms; Eye Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Retinal Neoplasms; Rituximab; Vitreous Body | 2021 |
A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2022 |
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab | 2022 |
Parameters of MR perfusion-weighted imaging predict the response and prognosis to high-dose methotrexate-based chemotherapy in immunocompetent patients with primary central nervous system lymphoma.
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Perfusion; Prognosis; Vascular Endothelial Growth Factor A | 2022 |
Efficacy of Boron Neutron Capture Therapy in Primary Central Nervous System Lymphoma: In Vitro and In Vivo Evaluation.
Topics: Animals; Apoptosis; Boron; Boron Neutron Capture Therapy; Brain; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Cranial Irradiation; Disease Models, Animal; Humans; Lymphoma; Methotrexate; Mice; Phenylalanine; Tissue Distribution | 2021 |
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2022 |
Outcome of Primary Central Nervous System Lymphoma Treated with Combined Surgical Resection and High- Dose Methotrexate Chemotherapy: A Single-Institution Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Retrospective Studies; Treatment Outcome | 2022 |
Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Imidazoles; Lymphoma; Methotrexate; Pyrimidines | 2022 |
Unusual primary central nervous system T-cell/histiocyte-rich large B-cell lymphoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Female; Histiocytes; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Middle Aged; Rituximab; T-Lymphocytes | 2022 |
Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Transplantation, Autologous | 2022 |
Isolated CNS relapse of blastic plasmacytoid dendritic cell neoplasm.
Topics: Adult; Central Nervous System Neoplasms; Dendritic Cells; Hematologic Neoplasms; Humans; Injections, Spinal; Male; Methotrexate; Myeloproliferative Disorders; Recurrence | 2022 |
High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Prospective Studies; Retrospective Studies; Rituximab | 2022 |
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Methotrexate; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Rituximab; Thiotepa; Transplantation, Autologous; Treatment Outcome; Young Adult | 2022 |
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Lomustine; Lymphoma; Methotrexate; Middle Aged; Procarbazine; Receptors, Thrombopoietin; Rituximab | 2022 |
Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Methotrexate; Middle Aged; Retrospective Studies | 2022 |
Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cost-Benefit Analysis; Cytarabine; Humans; Lymphoma; Methotrexate; Retrospective Studies | 2022 |
Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients ≥80 years treated with high-dose methotrexate-based chemotherapy.
Topics: Activities of Daily Living; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Methotrexate; Prognosis; Retrospective Studies; Treatment Outcome | 2022 |
Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System; Central Nervous System Neoplasms; Cranial Irradiation; Female; Humans; Imidazoles; Lymphoma, Non-Hodgkin; Male; Methotrexate; Pyrimidines; Retrospective Studies | 2022 |
Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Salvage Therapy | 2022 |
[Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lymphoma, Non-Hodgkin; Methotrexate; Myeloid Differentiation Factor 88; NF-kappa B; Phosphatidylinositol 3-Kinases; Procarbazine; Receptors, Chimeric Antigen; Rituximab; Thiotepa; Vincristine | 2022 |
The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Methotrexate; Rituximab; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous | 2022 |
About time: why central nervous system prophylaxis timing in diffuse large B-cell lymphoma matters and does the protocol need updating?
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Rituximab | 2022 |
Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2022 |
Cranial Radiation Therapy as Salvage in the Treatment of Relapsed Primary CNS Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Humans; Lymphoma; Methotrexate; Middle Aged; Retrospective Studies | 2022 |
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma; Methotrexate; Rituximab; Thiotepa | 2023 |
CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Topics: CD79 Antigens; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Mutation; Myeloid Differentiation Factor 88; Rituximab | 2023 |
Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cost-Benefit Analysis; Cytarabine; Humans; Lymphoma; Methotrexate; Retrospective Studies; Rituximab; Treatment Outcome | 2022 |
Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Eye Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Retinal Neoplasms; Retrospective Studies; Treatment Outcome; Vitreous Body | 2023 |
Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single-center real-world clinical experience.
Topics: Central Nervous System Neoplasms; Humans; Interleukin-10; Interleukin-6; Intraocular Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Treatment Outcome | 2023 |
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; COVID-19; Cytarabine; Humans; Ifosfamide; Lymphoma; Methotrexate; Pandemics; Prospective Studies; Rituximab; SARS-CoV-2; Vincristine | 2023 |
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Temozolomide | 2023 |
Primary Central Nervous System Lymphoma in an Immunocompetent Young Adult Patient: A Rare Case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Humans; Immunoglobulin G; Immunoglobulin M; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Procarbazine; Young Adult | 2023 |
Impact of triple intrathecal prophylaxis in acute lymphoblastic leukemia adults receiving HyperCVAD: A COVID-19 practice change.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; COVID-19; Cyclophosphamide; Humans; Methotrexate; Pandemics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Vincristine | 2023 |
Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Retrospective Studies | 2023 |
[A single-center, retrospective analysis of relapse and progression patterns of primary central nervous system lymphoma: can whole brain radiotherapy be replaced?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies | 2023 |
Cerebral delivery of redox-responsive lenalidomide prodrug plus methotrexate for primary central nerve system lymphoma combination therapy.
Topics: Brain Neoplasms; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma; Methotrexate; Oxidation-Reduction; Prodrugs | 2023 |
Management of primary and secondary CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Prospective Studies; Transplantation, Autologous | 2023 |
Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Retrospective Studies | 2023 |
Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma; Methotrexate; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2023 |
[Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Chronic Disease; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Risk Assessment; Rituximab; Vincristine | 2023 |
Eyewash with balanced salt solution after intravitreal methotrexate injection in a case of vitreoretinal lymphoma: a simple but effective way to prevent ocular surface toxicity.
Topics: Central Nervous System Neoplasms; Corneal Diseases; Eye Neoplasms; Humans; Intravitreal Injections; Lymphoma, Non-Hodgkin; Methotrexate; Retinal Neoplasms; Sodium Chloride; Vitreous Body | 2023 |
Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2023 |
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Induction Chemotherapy; Lymphoma; Methotrexate; Retrospective Studies; Teniposide | 2023 |
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, B-Cell; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Young Adult | 2023 |
Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Methotrexate; Middle Aged; Retrospective Studies; Rituximab | 2023 |
Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2019 |
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; White Matter | 2019 |
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2019 |
Contrast-Enhanced MRI Texture Parameters as Potential Prognostic Factors for Primary Central Nervous System Lymphoma Patients Receiving High-Dose Methotrexate-Based Chemotherapy.
Topics: Adult; Aged; Central Nervous System Neoplasms; Contrast Media; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies | 2019 |
Preparation and Characterization of Fe
Topics: 3T3 Cells; Animals; Apoptosis; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Liberation; Female; Ferric Compounds; Humans; Hyperthermia, Induced; Lymphoma; Magnetite Nanoparticles; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Temperature; Toxicity Tests, Acute | 2019 |
Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Lateral intraventricular primary central nervous system lymphoma (LIPCNSL): a review.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; China; Craniotomy; Disease Progression; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Databases, Factual; France; Humans; Lymphoma; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Progression-Free Survival; Retrospective Studies; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2020 |
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Central Nervous System; Central Nervous System Neoplasms; Cost-Benefit Analysis; Cytarabine; Humans; Methotrexate; Rituximab; Thiotepa | 2020 |
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cranial Irradiation; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; Internationality; Kaplan-Meier Estimate; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Organ Transplantation; Postoperative Complications; Progression-Free Survival; Proportional Hazards Models; Rituximab; Thiotepa | 2020 |
Bilateral Infiltrative Optic Neuropathy of Systemic Mantle Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Cytarabine; Fundus Oculi; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Optic Nerve; Optic Nerve Diseases; Rituximab | 2020 |
Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Size; Central Nervous System Neoplasms; Female; Humans; Kidney; Lymphoma; Male; Medical Records; Methotrexate; Middle Aged; Obesity; Retrospective Studies | 2020 |
Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Lymphoma; Metabolome; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; ras Proteins; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Isolated Central Nervous System Relapse Following Treatment Reduction in Low-risk Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System Neoplasms; Child; Child, Preschool; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Infant; Lebanon; Male; Methotrexate; Neoplasm Recurrence, Local; Non-Randomized Controlled Trials as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Survival Rate | 2020 |
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Progression-Free Survival; Proportional Hazards Models; Remission Induction; Retrospective Studies; Rituximab; United Kingdom | 2020 |
Methotrexate-associated lymphoproliferative disorders in the central nervous system and stomach: A case report.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Arthritis, Rheumatoid; Central Nervous System Neoplasms; Diagnosis, Differential; Endoscopy, Digestive System; Female; Gait Ataxia; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Rituximab; Stomach Neoplasms; Treatment Outcome | 2020 |
GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prognosis; Tumor Cells, Cultured | 2020 |
Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Topics: Central Nervous System; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Methotrexate | 2020 |
Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 2020 |
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Cytarabine; Delayed Diagnosis; Female; Follow-Up Studies; Humans; Immunocompetence; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
Topics: Aged; Central Nervous System Neoplasms; Female; Humans; Killer Cells, Natural; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Middle Aged; Models, Biological; Risk Factors | 2020 |
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Vincristine | 2020 |
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Off-Label Use; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Time Factors | 2020 |
Influence of MTHFR C677T Polymorphism on High-Dose Methotrexate-Related Toxicity in Patients With Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
Topics: Acute Kidney Injury; Adult; Aged; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Homozygote; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies | 2021 |
Real-time intracranial pressure monitoring during high-dose methotrexate treatment for primary central nervous system lymphoma.
Topics: Adult; Central Nervous System Neoplasms; Female; Humans; Intracranial Pressure; Lymphoma, Non-Hodgkin; Methotrexate | 2020 |
Gamma knife stereotactic radiosurgery as an effective tool in primary CNS lymphoma: Evaluation of stereotactic radiosurgery and methotrexate treatment in a prospective and observational clinical research study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Radiosurgery; Treatment Outcome | 2021 |
Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report.
Topics: Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Endocrine System Diseases; Hormone Replacement Therapy; Humans; Hypopituitarism; Hypothalamic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Treatment Outcome | 2021 |
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Immunoglobulins; Lymphoma; Macrophages; Male; Membrane Proteins; Methotrexate; Prognosis; Tumor Microenvironment | 2021 |
Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2021 |
Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Germany; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Prognosis; Recurrence; Retreatment; Survival Analysis; Treatment Outcome; Young Adult | 2021 |
Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: A case report.
Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Levofloxacin; Lymphoma; Methotrexate | 2021 |
Prophylactic high-dose methotrexate in diffuse large B cell lymphoma, authors' response.
Topics: Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate | 2021 |
Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma; caution required.
Topics: Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Progression-Free Survival; Retrospective Studies; Rituximab; Vincristine | 2022 |
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Vincristine | 2021 |
Successful treatment of CNS involvement in a patient with widely disseminated PTLD through the addition of intrathecal methotrexate to standard therapy.
Topics: Central Nervous System Neoplasms; Child; Humans; Injections, Spinal; Lymphoproliferative Disorders; Methotrexate; Organ Transplantation | 2021 |
Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Central Nervous System; Central Nervous System Neoplasms; Cranial Irradiation; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Retrospective Studies; Rituximab | 2021 |
Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mortality; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; United Kingdom; Vincristine | 2021 |
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Remission Induction; Retrospective Studies; Rituximab; Stem Cell Transplantation; Temozolomide; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Transplantation, Autologous | 2017 |
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Cerebrospinal Fluid; Child; Clinical Trials as Topic; Cranial Irradiation; Dexamethasone; Disease-Free Survival; Erythrocyte Count; Female; Humans; Leucovorin; Leukocyte Count; Male; Methotrexate; Polyethylene Glycols; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Survival Rate | 2017 |
Interim
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Positron-Emission Tomography; Registries; Retrospective Studies; Survival Rate | 2017 |
Targeted therapy of CNS leukemia?
Topics: Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Leukemia; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome; Young Adult | 2017 |
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Radiation Dosage; Retrospective Studies | 2017 |
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
Topics: Aged; Central Nervous System Neoplasms; Humans; Immunotherapy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2017 |
Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Immunohistochemistry; Male; Methotrexate; Middle Aged; Prognosis; Young Adult | 2017 |
Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Temozolomide; Vincristine | 2018 |
Primary central nervous system lymphoma in an immunocompetent patient: an unusual case of prolonged response to steroids.
Topics: Central Nervous System Neoplasms; Gadolinium; Humans; Immunocompetence; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Steroids | 2018 |
Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; China; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Nervous System Diseases; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2017 |
[Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Procarbazine; Rituximab; Treatment Outcome; Vincristine | 2017 |
Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leucovorin; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome; Vitamin B Complex | 2018 |
Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Desensitization, Immunologic; Dose-Response Relationship, Drug; Humans; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Premedication; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |
Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Exome Sequencing; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Methotrexate; Neoplasm Recurrence, Local; Nivolumab; Programmed Cell Death 1 Receptor; Remission Induction; T-Lymphocytes; Transplantation, Autologous; Treatment Outcome | 2018 |
Durable Complete Response of Primary CNS Lymphoma in an 80-Year-Old Patient with Retroviral Infection.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Central Nervous System Neoplasms; Humans; Lymphoma, AIDS-Related; Male; Methotrexate; Rituximab | 2017 |
[Not Available].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Genetic Heterogeneity; Humans; Immunophenotyping; Lymphoma; Methotrexate | 2015 |
Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC-MS/MS in patients receiving high-dose methotrexate therapy.
Topics: Calibration; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Folic Acid Antagonists; Humans; Kidney; Liver; Lymphoma, Non-Hodgkin; Male; Methotrexate; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration.
Topics: Administration, Intranasal; Animals; Antimetabolites, Antineoplastic; Brain; Central Nervous System Neoplasms; Drug Liberation; Hydrogels; Lymphoma; Male; Methotrexate; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution | 2018 |
Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Topics: Adult; Aged; Brain; Central Nervous System Neoplasms; Disease Progression; Eye; Eye Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies; Risk; Young Adult | 2019 |
High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: A case report.
Topics: Adult; Central Nervous System Neoplasms; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lymphoma; Male; Methotrexate; Renal Dialysis | 2018 |
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Leukemia, T-Cell; Male; Methotrexate; Rhabdomyolysis; Vincristine; Young Adult | 2018 |
Altered methotrexate clearance in the treatment of CNS lymphoma with concurrent use of nitrofurantoin for a urinary tract infection.
Topics: Aged; Central Nervous System Neoplasms; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Nitrofurantoin; Urinary Tract Infections | 2019 |
[Primary central nervous system lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; France; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local | 2016 |
A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Female; Humans; Immunotherapy; Lymphoma; Methotrexate; Rituximab | 2019 |
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Risk Factors; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2019 |
Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies | 2019 |
Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Chemoradiotherapy; Female; Humans; India; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Retrospective Studies; Rituximab; Survival Analysis; Temozolomide; Treatment Outcome | 2019 |
Primary central nervous system plasmablastic lymphoma in an HIV-positive patient.
Topics: Adult; Antimetabolites, Antineoplastic; Antiretroviral Therapy, Highly Active; Central Nervous System Neoplasms; Epstein-Barr Virus Infections; Herpesvirus 4, Human; HIV; HIV Infections; Humans; Male; Methotrexate; Plasmablastic Lymphoma; Rare Diseases; Sarcoma, Kaposi; Treatment Outcome | 2019 |
Intrathecal dose intensification by CNS status at diagnosis in the treatment of children with acute lymphoblastic leukemia.
Topics: Adolescent; Central Nervous System Neoplasms; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Infant; Injections, Spinal; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate | 2019 |
Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Methylenetetrahydrofolate Dehydrogenase (NADP); Minor Histocompatibility Antigens; Molecular Targeted Therapy; Peptide Synthases; Thymidylate Synthase | 2019 |
Therapeutic Outcomes and Toxicity of High-Dose Methotrexate-Based Chemotherapy for Elderly Patients with Primary Central Nervous System Lymphoma: A Report on Six Cases.
Topics: Aged, 80 and over; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate | 2019 |
Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.
Topics: Adult; Aged; Central Nervous System Neoplasms; Cohort Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Premedication; Prospective Studies; Recurrence; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
It's not all about the CNS. High dose methotrexate in DLBCL.
Topics: Central Nervous System Neoplasms; Freedom; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasm Recurrence, Local | 2019 |
[A case of secondary central nervous system lymphoma presenting marked hypoglycorrhachia].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Diagnostic Imaging; Doxorubicin; Glucose; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Oculomotor Nerve Diseases; Prednisolone; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2019 |
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Prednisone; Rituximab; Survival Rate; Vincristine | 2019 |
Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Central Nervous System Neoplasms; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Neutropenia; Procarbazine; Progression-Free Survival; Rituximab; Temozolomide; Vincristine | 2019 |
[Our experience with the treatment of primary lymphomas of the central nervous system].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Rituximab; Survival Rate | 2012 |
Primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Humans; Methotrexate; Middle Aged | 2013 |
Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Hydrocortisone; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged | 2013 |
Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cytarabine; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Radiotherapy Dosage; Retrospective Studies; Rituximab; Survival Rate; Young Adult | 2013 |
Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Cognition; Humans; Lymphoma; Methotrexate; Neuroimaging; Neuropsychological Tests; Prospective Studies; Quality of Life | 2013 |
Is there a role for radiotherapy in the primary management of primary central nervous system lymphoma? A single-centre case series.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Female; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Vincristine | 2013 |
Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving low-dose methotrexate treatment.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Central Nervous System Neoplasms; Female; Humans; Immunohistochemistry; Interleukin-2 Receptor alpha Subunit; Lymphoma; Lymphoproliferative Disorders; Methotrexate; Middle Aged; Treatment Outcome | 2013 |
Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Recent advances in treatment of primary central nervous system lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Methotrexate; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Salvage Therapy; Stem Cell Transplantation | 2013 |
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Methotrexate; Middle Aged; Survival Rate; Temozolomide; Young Adult | 2013 |
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Topics: Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate | 2011 |
The risk of CNS involvement in aggressive lymphomas in the rituximab era.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation, Autologous | 2013 |
Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004.
Topics: Adult; Aged; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Japan; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Surveys and Questionnaires; Survival Rate | 2014 |
Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Carmustine; Central Nervous System Neoplasms; Cesarean Section; Cytarabine; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Melphalan; Methotrexate; Podophyllotoxin; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Rituximab; Transplantation, Autologous; Treatment Outcome | 2014 |
Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasms; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Rituximab; Transplantation, Autologous; Treatment Outcome | 2014 |
Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Proportional Hazards Models; Retrospective Studies; Transcriptome; Treatment Outcome | 2014 |
Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Radiotherapy; Retrospective Studies; Risk Factors; Rituximab; Tertiary Care Centers; Treatment Outcome; Young Adult | 2014 |
Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neutropenia; Remission Induction; Temozolomide; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cytarabine; Dexamethasone; Female; Humans; Idarubicin; Lymphoma; Male; Methotrexate; Middle Aged; Multimodal Imaging; Neoplasm Staging; Prognosis; Rituximab | 2014 |
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma; Male; Methotrexate; Remission Induction; Thiotepa; Treatment Outcome | 2014 |
Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Retrospective Studies; Treatment Outcome | 2015 |
Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Castleman Disease; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Interactions; Etoposide; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, AIDS-Related; Methotrexate; Neoplasm Staging; Prednisolone; Prednisone; Radiotherapy, Adjuvant; Risk Assessment; Rituximab; Vincristine | 2014 |
Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Treatment Outcome; Young Adult | 2015 |
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Spinal; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasms; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2014 |
Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2014 |
Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Radiotherapy, Adjuvant; Teniposide; Young Adult | 2014 |
Therapeutic and survival outcomes following treatment of primary central nervous system lymphoma: a 12-year case study.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Cranial Irradiation; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Survival Rate; Time Factors | 2014 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Risk Assessment; Rituximab; Survival Rate; Vincristine; Young Adult | 2014 |
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
Topics: Antimetabolites, Antineoplastic; Ascitic Fluid; Central Nervous System Neoplasms; Child, Preschool; Cohort Studies; Combined Modality Therapy; Down-Regulation; Drainage; Female; Humans; Infant; Infant, Newborn; Leucovorin; Male; Metabolic Clearance Rate; Methotrexate; Neuroprotective Agents; Pericardial Effusion; Pleural Effusion, Malignant; Postoperative Complications; Retrospective Studies; Subdural Effusion | 2015 |
A simple but very important missing point about intrathecal chemotherapy.
Topics: Adolescent; Central Nervous System Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Injections, Spinal; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2016 |
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lymphoma; Male; Methotrexate; Middle Aged; Neuropsychological Tests; Prednisolone; Survival Analysis; Treatment Outcome; Vincristine | 2014 |
[Clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Idarubicin; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Remission Induction; Treatment Outcome | 2014 |
Delayed methotrexate excretion in infants and young children with central nervous system tumors and postoperative fluid collections.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Leucovorin; Male; Methotrexate; Neuroprotective Agents; Postoperative Complications; Subdural Effusion | 2015 |
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Humans; Immunosuppressive Agents; Lymphoma; Male; Methotrexate | 2015 |
Response to: comment on "Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections".
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Leucovorin; Male; Methotrexate; Neuroprotective Agents; Postoperative Complications; Subdural Effusion | 2015 |
Primary CNS lymphoma: a landmark trial and the next steps.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cranial Irradiation; Humans; Lymphoma; Male; Methotrexate; Treatment Outcome | 2015 |
Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Tomography, X-Ray Computed | 2015 |
Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2015 |
Neuro-oncology: Primary CNS lymphoma treatment--the devil is in the details.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cranial Irradiation; Humans; Lymphoma; Male; Methotrexate; Treatment Outcome | 2015 |
Treatment of young children with CNS-positive acute lymphoblastic leukemia without cranial radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate | 2015 |
A Demyelinating Disease; What Lies Beneath?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Demyelinating Diseases; Diagnosis, Differential; Doxorubicin; Encephalomyelitis, Acute Disseminated; Etoposide; Humans; Hydrocortisone; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Methotrexate; Prednisone; Vincristine | 2016 |
Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Central Nervous System Neoplasms; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leucovorin; Lymphoma; Male; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Retrospective Studies; Vincristine | 2015 |
Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Rituximab; Young Adult | 2015 |
Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy.
Topics: Adult; Aged; Central Nervous System Neoplasms; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Nervous System Neoplasms; Cohort Studies; Cyclophosphamide; Cytarabine; Databases, Factual; Dexamethasone; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, bcl-2; Genes, myc; Germinal Center; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-6; Rituximab; Survival Rate; Vincristine | 2016 |
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2016 |
High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Fatal Outcome; Female; Histiocytic Sarcoma; Humans; Methotrexate; Middle Aged; Remission Induction | 2016 |
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Methotrexate; Middle Aged; Prognosis; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous; Vincristine | 2016 |
Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Eye Neoplasms; Female; Humans; Immunosuppressive Agents; Injections, Spinal; Intraocular Lymphoma; Intravitreal Injections; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Radiotherapy; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Visual Acuity; Vitrectomy | 2017 |
The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Transplantation, Autologous; Young Adult | 2016 |
Central nervous system involvement in T-cell lymphoma: A single center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Glioblastoma; Humans; Incidence; Injections, Spinal; Lactate Dehydrogenases; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Young Adult | 2016 |
Defining optimal initial therapy for primary CNS lymphoma.
Topics: Central Nervous System Neoplasms; Cytarabine; Humans; Methotrexate; Rituximab; Thiotepa | 2016 |
Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Brain; Central Nervous System Neoplasms; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Female; Humans; Immunocompromised Host; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Reproducibility of Results; Retrospective Studies; ROC Curve | 2016 |
High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Central Nervous System Neoplasms; Cytokines; Female; Humans; Immunophenotyping; Intraocular Lymphoma; Intravitreal Injections; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Methotrexate; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2017 |
Long-term survival in AIDS-related primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Retroviral Agents; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Lymphoma, AIDS-Related; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2017 |
Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Young Adult | 2017 |
Intravitreal injections of methotrexate in treatment of primary central nervous system lymphoma with intraocular involvement.
Topics: Aged; Brain; Central Nervous System Neoplasms; Eye; Fatal Outcome; Humans; Intravitreal Injections; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate | 2016 |
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab | 2017 |
[Clinicopathological Features of Primary Central Nervous System Lymphoma and Their Influence on Prognosis of Desease].
Topics: Aged; Brain Neoplasms; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Methotrexate; Prognosis; Rituximab | 2016 |
High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Rate | 2017 |
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis | 2008 |
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood Cell Count; Central Nervous System Neoplasms; Chemoprevention; Child; Clinical Protocols; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Methotrexate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction | 2008 |
Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
High-dose methotrexate for elderly patients with primary CNS lymphoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Central Nervous System Neoplasms; Enzyme Inhibitors; Etoposide; Female; Humans; Injections, Intra-Arterial; Injections, Intravenous; Lymphoma, Large-Cell, Immunoblastic; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Organophosphorus Compounds | 2008 |
Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Central Nervous System Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Methotrexate; Middle Aged | 2008 |
Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.
Topics: Antimetabolites, Antineoplastic; Brain; Central Nervous System Neoplasms; Cystathionine beta-Synthase; Female; Humans; Hydroxymethyl and Formyl Transferases; Lymphoma; Male; Methionine; Methionine Sulfoxide Reductases; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Microfilament Proteins; Middle Aged; Multienzyme Complexes; Nucleotide Deaminases; Oxidoreductases; Polymorphism, Genetic; Prospective Studies; Tetrahydrofolate Dehydrogenase; Transcobalamins; Transcription Factors; TRPM Cation Channels | 2009 |
[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mucositis; Retrospective Studies; Young Adult | 2008 |
Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Injections, Spinal; Leukemia, Myeloid, Acute; Liposomes; Longitudinal Studies; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Registries; Spain | 2008 |
Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; CD3 Complex; Central Nervous System Neoplasms; Epstein-Barr Virus Infections; Female; Humans; Immune Tolerance; Immunoglobulin Heavy Chains; Immunosuppressive Agents; Lymphoma; Male; Methotrexate; Rituximab; Tomography Scanners, X-Ray Computed | 2008 |
Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System Neoplasms; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2008 |
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Central Nervous System Neoplasms; Female; Humans; Image Enhancement; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate; Rats; Rats, Nude; Rituximab; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Primary central nervous system lymphoma: an unusual presentation.
Topics: Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate | 2008 |
Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; DNA-Binding Proteins; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Proto-Oncogene Proteins c-bcl-6 | 2009 |
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
Topics: Antimetabolites, Antineoplastic; Blood-Brain Barrier; Brain Neoplasms; Central Nervous System Neoplasms; Disease-Free Survival; Drug Delivery Systems; Humans; Infusions, Intra-Arterial; Lymphoma, Non-Hodgkin; Methotrexate; Osmosis; Prognosis; Treatment Outcome | 2009 |
A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies | 2009 |
[Lymphoma of the pituitary stalk].
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Methotrexate; Pituitary Neoplasms; Spinal Puncture; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Progress in primary CNS lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Lymphoma; Methotrexate; Randomized Controlled Trials as Topic | 2009 |
CXCL13 and CXCL12 in central nervous system lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Central Nervous System Neoplasms; Chemokine CXCL12; Chemokine CXCL13; Disease Progression; Female; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis | 2009 |
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Drug Administration Schedule; Epidural Space; Female; Humans; Hungary; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2009 |
Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Central Nervous System Neoplasms; Epstein-Barr Virus Infections; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Mycophenolic Acid; Rituximab | 2010 |
Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Brain; Central Nervous System Neoplasms; Humans; Lamivudine; Lymphoma, T-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Pyrrolidinones; Raltegravir Potassium; Stavudine; Treatment Outcome | 2010 |
Central nervous system involvement at the time of presentation in acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Mercaptopurine; Methotrexate; Oncogene Proteins, Fusion; Radiotherapy; Sarcoma, Myeloid; Tretinoin | 2010 |
Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma.
Topics: Adult; Aged; Antigens, CD; Central Nervous System Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Female; Follow-Up Studies; Humans; Immunohistochemistry; Immunosuppressive Agents; Interferon Regulatory Factors; Lymphoma; Male; Methotrexate; Middle Aged; Proto-Oncogene Proteins c-bcl-6; Survival Analysis; Time Factors | 2010 |
Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Cohort Studies; Female; Humans; Immunosuppressive Agents; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Analysis; Young Adult | 2010 |
Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy.
Topics: Adult; Aged; B-Lymphocytes; CD79 Antigens; Cell Differentiation; Central Nervous System Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Female; Humans; Immunosuppressive Agents; Interferon Regulatory Factors; Lymphoma; Male; Methotrexate; Middle Aged; Neprilysin; Proto-Oncogene Proteins c-bcl-6; Retrospective Studies; Syndecan-1 | 2010 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma presenting as lower body parkinsonism.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Cranial Irradiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Lymphoma; Methotrexate; Middle Aged; Parkinsonian Disorders | 2010 |
Concurrent administration of intravenous systemic and intravitreal methotrexate for intraocular lymphoma with central nervous system involvement.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Drug Administration Routes; Eye Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Invasiveness; Treatment Outcome | 2010 |
Hematology. Individualized methotrexate dosing in primary CNS lymphoma.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Hematologic Tests; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Treatment Outcome | 2010 |
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Risk; Rituximab; Vincristine | 2010 |
[High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Rate | 2010 |
Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Fever; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Lupus Nephritis; Lymphoma; Methotrexate; Mycophenolic Acid; Neurotoxicity Syndromes; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2011 |
Flows and flaws in primary central nervous system lymphoma.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Central Nervous System Neoplasms; Cytarabine; Decision Making; Drug Therapy, Combination; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Treatment Outcome | 2010 |
Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Statistics as Topic; Time Factors; Treatment Outcome | 2010 |
Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Epidemiologic Methods; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prognosis; Treatment Outcome | 2010 |
Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
Topics: Adolescent; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Immunocompetence; Infant; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Treatment Outcome | 2010 |
Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis; Radiotherapy; Radiotherapy Dosage; Regression Analysis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2011 |
Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prognosis; Recurrence; Republic of Korea; Retrospective Studies; Survival Analysis; Young Adult | 2011 |
A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Nitrosourea Compounds; Procarbazine; Retrospective Studies | 2010 |
How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Cytarabine; Disease-Free Survival; Humans; Ifosfamide; Lymphoma; Methotrexate; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.
Topics: Adult; Antimetabolites, Antineoplastic; Case-Control Studies; Central Nervous System Neoplasms; Child; Cohort Studies; Genetic Predisposition to Disease; Humans; Injections, Spinal; Meningioma; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radiotherapy; Risk Factors; United Kingdom | 2010 |
Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma.
Topics: Aged; Aging; Central Nervous System Neoplasms; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Diseases; Longitudinal Studies; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Statistics, Nonparametric | 2011 |
Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent patients.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Immunocompetence; Infant; Lymphoma; Male; Methotrexate; Treatment Outcome | 2011 |
Epstein-Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time?
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System; Central Nervous System Neoplasms; Comorbidity; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; In Situ Hybridization; Incidence; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Retrospective Studies; RNA, Viral; Treatment Outcome | 2011 |
Late relapse in primary central nervous system lymphoma: clonal persistence.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Central Nervous System Neoplasms; DNA-Binding Proteins; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prognosis; Proto-Oncogene Proteins c-bcl-6; Treatment Outcome | 2011 |
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Recurrence; Treatment Outcome | 2011 |
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Cell Line, Tumor; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate; Random Allocation; Rats; Rats, Nude; Rituximab; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2011 |
Diffuse infiltrating retinoblastoma with central nervous system metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Etoposide; Humans; Hydrocortisone; Infusions, Intravenous; Injections, Spinal; Magnetic Resonance Imaging; Male; Methotrexate; Retinal Neoplasms; Retinoblastoma; Vincristine | 2011 |
Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Contrast Media; Disease-Free Survival; DNA-Binding Proteins; Drug Administration Schedule; Female; Follow-Up Studies; Gadolinium; Humans; Interferon Regulatory Factors; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Odds Ratio; Procarbazine; Prospective Studies; Recurrence; Regulatory Factor X Transcription Factors; Severity of Illness Index; Transcription Factors; Tumor Suppressor Protein p53; Vincristine; X-Box Binding Protein 1 | 2011 |
High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2011 |
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Topics: Central Nervous System Neoplasms; Female; Humans; Male; Methotrexate | 2011 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Vindesine | 2011 |
Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Injections, Spinal; Karnofsky Performance Status; Lomustine; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Neuroprotective Agents; Procarbazine; Retrospective Studies; Young Adult | 2012 |
Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Middle Aged; Recurrence; Remission Induction | 2011 |
Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Prognosis; Recurrence; Rituximab; Treatment Outcome | 2012 |
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Age of Onset; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Germany; Humans; International Cooperation; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Grading; Neoplasm Invasiveness; Prednisolone; Prednisone; Rituximab; Societies, Medical; Vincristine; Young Adult | 2012 |
Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
Topics: Adult; Aged; Aged, 80 and over; Brain; Central Nervous System Neoplasms; Cognition; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neuropsychological Tests; Quality of Life | 2012 |
The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Treatment Outcome | 2012 |
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Cytarabine; Dacarbazine; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Nervous System; Temozolomide | 2012 |
Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Statistics, Nonparametric; Survival Rate | 2012 |
Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Diagnostic Imaging; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Middle Aged; Procarbazine; Recurrence; Rituximab; Vincristine | 2012 |
Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.
Topics: Abdominal Pain; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Colon; Colonic Pseudo-Obstruction; Decompression, Surgical; Dilatation, Pathologic; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neostigmine; Parasympathomimetics; Risk Factors; Treatment Outcome | 2012 |
[Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Forkhead Transcription Factors; Humans; Immunophenotyping; Interferon Regulatory Factors; Ki-67 Antigen; LIM Domain Proteins; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Neprilysin; Positive Regulatory Domain I-Binding Factor 1; Prednisone; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Repressor Proteins; Retrospective Studies; Serpins; Survival Rate; Vincristine; Young Adult | 2012 |
[I. Treatment and problem of primary central nerve system lymphoma].
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Humans; Lymphoma; Methotrexate | 2012 |
[II. Primary treatment of CNS lymphoma with high-dose MTX].
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemoradiotherapy; Humans; Lymphoma; Methotrexate | 2012 |
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Procarbazine; Prognosis; Survival Rate; Time Factors; Vincristine | 2012 |
Post-treatment T1 shortening in primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Central Nervous System Neoplasms; Female; Genotype; Humans; Lymphoma; Male; Methionine; Methotrexate; Middle Aged; Mutation, Missense; Survival Analysis; Transcobalamins | 2012 |
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cranial Nerve Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Eye Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2013 |
Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2012 |
Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dexamethasone; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Rituximab; Survival Rate | 2013 |
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Control Studies; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Injections, Spinal; Lymphoma; Male; Methotrexate; Middle Aged; Nervous System; Retrospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease-Free Survival; Eye Neoplasms; Female; Humans; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Remission Induction; Retrospective Studies; Safety; Survival Rate; Visual Acuity; Vitreous Body | 2002 |
Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Hydrocortisone; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study.
Topics: Adolescent; Age Factors; Central Nervous System Neoplasms; Child; Child, Preschool; Disease-Free Survival; Female; Hong Kong; Humans; Immunophenotyping; Infant; Logistic Models; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Regression Analysis; Salvage Therapy; Time Factors | 2003 |
BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Cell Differentiation; Central Nervous System Neoplasms; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; Female; Humans; Hyaluronan Receptors; Immunohistochemistry; In Situ Hybridization, Fluorescence; Interferon Regulatory Factors; Lymphoma; Male; Membrane Glycoproteins; Methotrexate; Middle Aged; Neprilysin; Polymerase Chain Reaction; Prognosis; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Syndecan-1; Syndecans; Transcription Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2003 |
Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome | 2002 |
Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Organophosphorus Compounds; Radioimmunotherapy; Recurrence; Rituximab; Time Factors | 2003 |
Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Disease-Free Survival; Eye Neoplasms; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local | 2003 |
Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Time Factors | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Safety; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
Intravitreal methotrexate injections for intraocular involvement in primary central nervous system lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Eye Neoplasms; Fluorescein Angiography; Fundus Oculi; Humans; Injections; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Visual Acuity; Vitreous Body | 2003 |
Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Disease-Free Survival; Female; Humans; Infant; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2004 |
CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child, Preschool; Cohort Studies; Cranial Irradiation; Female; Humans; Infant; Leukemia, T-Cell; Male; Methotrexate; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate | 2004 |
Neurocognitive outcomes in primary CNS lymphoma (PCNSL).
Topics: Aged; Central Nervous System Neoplasms; Cognition Disorders; Combined Modality Therapy; Comorbidity; Cranial Irradiation; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Invasiveness; Radiation Injuries; Treatment Outcome | 2004 |
Cognitive functions in survivors of primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Attention; Brain; Central Nervous System Neoplasms; Cognition Disorders; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Memory; Methotrexate; Middle Aged; Myelin Sheath; Neuropsychological Tests; Prospective Studies; Quality of Life; Remission Induction; Survivors | 2004 |
Cognitive status and quality of life after treatment for primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Carmustine; Case-Control Studies; Central Nervous System Neoplasms; Cognition Disorders; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Humans; Hydrocortisone; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Myelin Sheath; Neuropsychological Tests; Prospective Studies; Quality of Life; Teniposide | 2004 |
Primary CNS lymphoma: 5-year survival in relation to dosage of methotrexate and radiation.
Topics: Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; Radiotherapy, Adjuvant; Survival Rate | 2004 |
Systemic anaphylactic reaction following intrathecal administration of methotrexate in adult patient with primary central nervous system lymphoma.
Topics: Anaphylaxis; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Injections, Spinal; Male; Methotrexate; Middle Aged | 2004 |
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2004 |
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Survival Analysis; Vincristine | 2004 |
Primary central nervous system lymphoma with testicular relapse.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Recurrence; Testicular Neoplasms | 2004 |
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; CpG Islands; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Membrane Transport Proteins; Methotrexate; Methylation; Middle Aged; Predictive Value of Tests; Prevalence; Reduced Folate Carrier Protein; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2004 |
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cranial Irradiation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2004 |
The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Prednisone; Survival Rate; Vincristine | 2005 |
[Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Neoplasms; Central Nervous System Neoplasms; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Infant, Newborn; Male; Mercaptopurine; Methotrexate; Poland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Secondary Prevention; Survival Analysis; Testicular Neoplasms; Time Factors; Treatment Outcome; Vincristine | 2004 |
Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aspartic Acid; Central Nervous System Neoplasms; Choline; Creatine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Immunocompetence; Lactic Acid; Lipid Metabolism; Lymphoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Protons; Survival Analysis | 2005 |
Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, MDR; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Multidrug Resistance-Associated Protein 2; Radiography; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Pneumonia; Prednisone; Procarbazine; Retrospective Studies; Sepsis; Vincristine | 2005 |
MTX-induced white matter changes are associated with polymorphisms of methionine metabolism.
Topics: Aged; Brain; Central Nervous System Neoplasms; Demyelinating Diseases; DNA Mutational Analysis; Drug Resistance; Female; Folic Acid; Folic Acid Antagonists; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Haplotypes; Humans; Lymphoma; Male; Methionine; Methotrexate; Middle Aged; Myelin Sheath; Nerve Fibers, Myelinated; Neurotoxins; Polymorphism, Genetic; Risk Factors; S-Adenosylmethionine | 2005 |
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Child, Preschool; Cohort Studies; Female; Health Status; Humans; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Survival Analysis | 2005 |
Myelopathy due to intrathecal chemotherapy: report of six cases.
Topics: Adolescent; Central Nervous System Neoplasms; Child; Child, Preschool; Female; Folic Acid Antagonists; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Spinal Cord Diseases | 2005 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasm Recurrence, Local; Procarbazine; Temozolomide; Vincristine | 2005 |
Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System Neoplasms; Chemoprevention; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Patient Selection; Practice Patterns, Physicians'; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Surveys and Questionnaires; United Kingdom | 2005 |
Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cognition Disorders; Cytarabine; Drug Screening Assays, Antitumor; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Middle Aged; Prospective Studies; Treatment Outcome | 2003 |
Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Epichlorohydrin; Humans; Imidazoles; Lymphoma; Male; Methotrexate; Middle Aged; Resins, Synthetic | 2005 |
Primary central nervous system lymphoma in a renal transplant recipient with Bardet-Biedl syndrome.
Topics: Adult; Antineoplastic Agents; Bardet-Biedl Syndrome; Central Nervous System Neoplasms; Combined Modality Therapy; Creatinine; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lymphoma; Methotrexate; Postoperative Complications | 2005 |
Low-grade central nervous system lymphoma: clarity through a hazy lens.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Methotrexate; T-Lymphocytes | 2006 |
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
Topics: Central Nervous System Neoplasms; Follow-Up Studies; Humans; Lymphoma; Magnetic Resonance Imaging; Methotrexate; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies | 2006 |
Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Karnofsky Performance Status; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Humans; Hydrocortisone; Incidence; Lactate Dehydrogenases; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis | 2006 |
Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Central Nervous System Neoplasms; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Regression, Spontaneous; Procarbazine; Treatment Outcome; Vincristine | 2006 |
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain; Central Nervous System Neoplasms; Cohort Studies; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Treatment Outcome | 2006 |
Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Injections, Spinal; Medical Records; Methotrexate; Middle Aged; Neoplasm Metastasis; Philippines; Pregnancy; Retrospective Studies; Survival Analysis; Uterine Neoplasms; Vincristine | 2006 |
Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Radiotherapy; Time Factors; Treatment Outcome; Vincristine | 2007 |
The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cytarabine; Female; Follow-Up Studies; Humans; Incidence; Injections, Spinal; Kaplan-Meier Estimate; London; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Time Factors; Treatment Outcome | 2007 |
Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?
Topics: Central Nervous System; Central Nervous System Neoplasms; Child; Clinical Trials as Topic; Humans; Leucovorin; Methotrexate; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Recurrence; Risk | 2006 |
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
Topics: Adult; Antibodies, Monoclonal; Blood-Brain Barrier; Brain; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Prognosis; Radioimmunotherapy; Remission Induction | 2006 |
[Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Doxorubicin; Facial Paralysis; Humans; Injections, Spinal; Male; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Risk Factors; Sagittal Sinus Thrombosis; Vincristine | 2006 |
High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Brain Neoplasms; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Recurrence; Stereotaxic Techniques | 2007 |
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome | 2007 |
Testicular relapse of primary central nervous system lymphoma.
Topics: Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Recurrence; Remission Induction; Testicular Neoplasms; Treatment Outcome | 2007 |
Toothache, paresthesia, and Horner syndrome: an unusual presentation of disseminated Burkitt's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System Neoplasms; Cyclophosphamide; Dry Socket; Horner Syndrome; Humans; Male; Mandibular Neoplasms; Methotrexate; Middle Aged; Paresthesia; Remission Induction; Tooth Extraction; Toothache; Vincristine | 2007 |
Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
Topics: Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Procarbazine; Vincristine | 2007 |
Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Logistic Models; Male; Methotrexate; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk | 2007 |
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Central Nervous System Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; HIV Seronegativity; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Rituximab | 2007 |
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Humans; Immunotherapy; Lymphoma; Male; Methotrexate; Middle Aged; Procarbazine; Prospective Studies; Remission Induction; Rituximab; Treatment Outcome; Vincristine | 2007 |
Perioperative complications of blood brain barrier disruption under general anesthesia: a retrospective review.
Topics: Adult; Anesthesia Recovery Period; Anesthesia, General; Antimetabolites, Antineoplastic; Blood-Brain Barrier; Carotid Arteries; Central Nervous System Neoplasms; Electrocardiography; Female; Gadolinium; Humans; Hypertonic Solutions; Infusions, Intra-Arterial; Intraoperative Complications; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Postoperative Complications; Postoperative Nausea and Vomiting; Retrospective Studies; Seizures; Tachycardia; Tomography, X-Ray Computed; Vertebral Artery | 2008 |
High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2008 |
Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Humans; Liver Transplantation; Lymphoma, Non-Hodgkin; Male; Methotrexate; Postoperative Complications; Tomography, X-Ray Computed | 2008 |
Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carboplatin; Central Nervous System Neoplasms; Eye Neoplasms; Female; Humans; Infusions, Intravenous; Injections; Lymphoma, Non-Hodgkin; Macula Lutea; Male; Methotrexate; Middle Aged; Retinal Diseases; Retrospective Studies; Tomography, X-Ray Computed; Vitreous Body | 2008 |
Results of treatment of 112 cases of primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cognition; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Leucovorin; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine | 2008 |
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Spinal; Life Tables; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies; Risk Factors; Survival Rate; Vincristine | 1995 |
[Central nervous system relapses in acute lymphoblastic leukemia and different methods of prophylaxis].
Topics: Adolescent; Adult; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Risk Factors; Survival Analysis | 1995 |
An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Child; Child, Preschool; Clinical Protocols; Combined Modality Therapy; Critical Care; Female; Humans; Infant; Injections, Intravenous; Injections, Spinal; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Recurrence; Remission Induction; Time Factors | 1995 |
Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Central Nervous System Neoplasms; Child; Cranial Irradiation; Cross-Sectional Studies; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Injections, Spinal; Italy; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasms, Second Primary; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Registries; Risk Factors; Wilms Tumor | 1994 |
Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer.
Topics: Absenteeism; Adolescent; Analysis of Variance; Central Nervous System Neoplasms; Child; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Humans; Injections, Spinal; Intelligence; Intelligence Tests; Leukemia; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasms; Neuropsychological Tests | 1994 |
Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.
Topics: Adult; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Leucovorin; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 1994 |
M-Bacod as first treatment for primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Leucovorin; Lymphoma; Methotrexate; Middle Aged; Vincristine | 1996 |
Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Treatment Outcome; Vincristine | 1996 |
Carboxypeptidase G2 rescue after high-dose methotrexate.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; gamma-Glutamyl Hydrolase; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects | 1996 |
[Long-term survivor (15 years) following central nervous system involvement in B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Humans; Lymphoma, B-Cell; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm Invasiveness; Prednisolone; Survivors; Vincristine | 1996 |
Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Blood-Brain Barrier; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Diuretics, Osmotic; Eye Neoplasms; Female; Humans; Injections; Lymphoma; Male; Mannitol; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Visual Acuity; Vitreous Body | 1997 |
Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis | 1997 |
Long-term survival in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1998 |
Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Disease Progression; Etoposide; Female; Humans; Lymphoma, AIDS-Related; Male; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dexamethasone; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Procarbazine; Radiography; Treatment Outcome | 1998 |
Chemotherapy is effective as early treatment for primary central nervous system lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Tomography, X-Ray Computed; Vincristine | 1999 |
[A case of non-Hodgkin lymphoma in the central nervous system, developing during treatment of galactorrhea amenorrhea syndrome].
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Galactorrhea; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Methotrexate; Prednisone; Syndrome; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1999 |
Primary central nervous system lymphoma: a clinicopathological study of 28 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Cognition Disorders; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Injections, Intraventricular; Lymphoma; Male; Methotrexate; Middle Aged; Spinal Cord Neoplasms; Survival Analysis; Time Factors | 2000 |
Methotrexate concentration in cerebrospinal fluid of the space created by tumor removal.
Topics: Area Under Curve; Central Nervous System Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Methotrexate | 2000 |
Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Glioblastoma; Humans; Methotrexate; Nimustine; Valproic Acid | 2000 |
Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Female; Humans; Injections, Spinal; Logistic Models; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prognosis; Risk Factors; Secondary Prevention; Survival Analysis | 2000 |
Primary central nervous system lymphoma and subcutaneous metastases.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Skin; Skin Neoplasms | 2000 |
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Infusions, Intravenous; Lymphoma; Male; Methotrexate; Middle Aged; Radiotherapy; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphoma; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Procarbazine; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
High-dose methotrexate for primary CNS lymphoma in the elderly.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Methotrexate; Retrospective Studies; Survival Analysis | 2000 |
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Injections, Intraventricular; Lymphoma; Male; Methotrexate; Middle Aged; Pilot Projects; Survival Analysis; Treatment Outcome | 2001 |
Primary central nervous system T-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cytarabine; Fatal Outcome; Humans; Lymphoma, T-Cell; Male; Methotrexate; Neoplasm Recurrence, Local; Prognosis | 2001 |
High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Brain; Brain Neoplasms; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Recurrence; Testicular Neoplasms | 2001 |
5. Report on workshop: Primary CNS lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Central Nervous System Neoplasms; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Gene Rearrangement; Humans; Injections, Spinal; Lymphoma, Non-Hodgkin; Methotrexate; Radiation Injuries; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2001 |
Neuropsychologic impairment in adult bone marrow transplant candidates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Attention; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cranial Irradiation; Cytarabine; Female; Humans; Leukemia; Lymphoma; Male; Memory; Methotrexate; Middle Aged; Neuropsychology; Psychomotor Performance; Regression Analysis; Whole-Body Irradiation | 1992 |
Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Central Nervous System Neoplasms; Cerebral Cortex; Child; Child, Preschool; Female; Humans; Injections, Intravenous; Injections, Spinal; Lymphoma; Magnetic Resonance Imaging; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies | 1992 |
Intracerebral (parenchymal) infusion of methotrexate: report of a case.
Topics: Adult; Brain; Central Nervous System Neoplasms; Cerebral Ventricles; Female; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Methotrexate; Tomography, X-Ray Computed | 1992 |
[Late recurrence (11 years) in a case of ALL. Recurrence or a second disease?].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Diagnosis, Differential; Humans; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Time Factors; Vincristine | 1992 |
Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Survival Analysis; Vincristine | 1991 |
Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; HIV Seropositivity; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Vincristine | 1991 |
Cognitive function in children with leukemia. Effect of radiation dose and time since irradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Child; Child, Preschool; Cognition; Combined Modality Therapy; Cranial Irradiation; Educational Status; Female; Humans; Infant; Intelligence; Male; Methotrexate; Motor Skills; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Remission Induction; Time Factors | 1991 |